

EAU Guidelines on Testicular Cancer

D. Nicol (Chair), D.M. Berney, J.L. Boormans,
D. Di Nardo (Patient advocate), C.D. Fankhauser,
S. Fischer, H. Gremmels (Patient advocate),
A. Heidenreich, R. Leão, N. Nicolai, C. Oing,
A. Patrikidou, T. Tandstad
Guidelines Associates: I. de Angst, W. Cazzaniga,
C. Gravina, F. Janisch,
Consultant radiologist: Y. Jain
Guidelines Office: N. Schouten

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	5
	1.1 Aim and objectives	5
	1.2 Panel composition	5
	1.3 Available publications	5
	1.4 Publication history and summary of changes	5
	1.4.1 Publication history	5
	1.4.2 Summary of changes	5
2.	METHODS	5
	2.1 Introduction	5
	2.2 Review	6
	2.3 Future goals	6
3.	EPIDEMIOLOGY, AETIOLOGY & PATHOLOGY	6
	3.1 Epidemiology and Aetiology	6
	3.2 Histological classification	7
4.	STAGING & PROGNOSIS	8
	4.1 Staging	8
	4.2 The Union for International Cancer Control prognostic groups	9
	4.3 Risk factors for relapse in clinical stage I testicular cancer	10
	4.4 The International Germ Cell Cancer Collaborative Group (IGCCCG) classification for the prognostic risk groups of metastatic germ cell cancer	10
5.	DIAGNOSTIC EVALUATION	12
	5.1 Physical examination	12
	5.2 Imaging	12
	5.2.1 Primary tumour	12
	5.2.2 Staging	12
	5.3 Serum tumour markers	13
	5.3.1 Pre-operative serum tumour markers	13
	5.3.2 Serum tumour markers after orchidectomy	13
	5.3.3 Other tumour markers	13
	5.4 Inguinal exploration and initial management	13
	5.4.1 Orchidectomy	13
	5.4.2 Testis-sparing surgery	13
	5.4.3 Insertion of testicular prosthesis	14
	5.4.4 Contralateral biopsy	14
	5.5 Pathological examination of the testis	14
	5.6 Screening	17
	5.7 Summary of evidence and recommendations for the diagnosis and staging of Testicular Cancer	17
6.	DISEASE MANAGEMENT	18
	6.1 Stage I germ cell tumours	18
	6.1.1 Germ cell neoplasia " <i>in situ</i> " (GCNIS)	18
	6.1.2 Seminoma germ cell tumour clinical stage I	18
	6.1.2.1 Surveillance	18
	6.1.2.2 Adjuvant chemotherapy	18
	6.1.2.3 Adjuvant radiotherapy	18
	6.1.2.4 Summary of evidence and recommendations for the treatment of clinical stage I seminoma germ cell tumour of the testis	19

6.1.3	Non-seminomatous germ cell tumours clinical stage I	19
6.1.3.1	Surveillance	20
6.1.3.2	Retroperitoneal lymph node dissection	20
6.1.3.3	Adjuvant chemotherapy	20
6.1.3.4	Risk-adapted treatment	21
6.1.3.5	Post-pubertal teratoma with somatic malignant component	21
6.1.3.6	Summary of evidence and recommendations for the treatment of clinical stage I non-seminoma germ cell tumour of the testis	21
6.1.3.7	Recommendations for risk-adapted treatment for clinical stage I non-seminomatous germ cell tumour based on vascular invasion	22
6.2	Metastatic germ cell tumours	23
6.2.1	Clinical stage I with (persistently) elevated serum tumour markers	23
6.2.2	Metastatic disease (stage IIA/B)	23
6.2.2.1	Stage IIA/B seminoma	23
6.2.2.1.1	Retroperitoneal lymph node dissection	23
6.2.2.1.2	De-escalating approaches	24
6.2.2.2	Stage II A/B non-seminoma (NSGCT)	25
6.2.2.2.1	Serum tumour marker negative	25
6.2.2.2.2	Serum tumour marker positive	27
6.2.3	Metastatic disease (stage II C and III)	27
6.2.3.1	Primary chemotherapy	27
6.2.3.1.1	Good-prognosis risk group - seminomatous germ cell tumour	27
6.2.3.1.2	Intermediate-prognosis risk group - seminomatous germ cell tumour	27
6.2.3.1.3	Good-prognosis risk group - non-seminomatous germ cell tumour	27
6.2.3.1.4	Intermediate-prognosis risk group - non-seminomatous germ cell tumour	27
6.2.3.1.5	Poor-prognosis risk group - non-seminomatous germ cell tumour	27
6.2.3.1.6	Prevention of thromboembolism events during chemotherapy	28
6.2.3.1.7	Guidelines for the Prevention of thromboembolism events during chemotherapy	29
6.3	Treatment evaluation and further treatment	29
6.3.1	Treatment evaluation	29
6.3.2	Residual tumour resection	29
6.3.2.1	Seminoma	29
6.3.2.2	Non-seminoma	30
6.3.3	Sequencing of surgery in the case of multiple sites	30
6.3.3.1	Quality and intensity of surgery	31
6.3.3.2	Salvage and desperation surgery	31
6.3.3.3	Consolidation chemotherapy after secondary surgery	31
6.3.4	Systemic salvage treatment for relapse or refractory disease	31
6.3.5	Second relapse	33
6.3.5.1	Late relapse (more than two years after end of first-line treatment)	33
6.3.6	Treatment of brain metastases	33
6.3.6.1	Guidelines for the treatment of metastatic testicular germ cell tumours	34
7.	FOLLOW-UP AFTER CURATIVE THERAPY	35
7.1	Minimal recommendations for follow-up	35
7.2	Quality of life and long-term toxicities after cure of testicular cancer	37
8.	RARE ADULT PARA- AND TESTICULAR TUMOURS	37
8.1	Classification	37
8.2	Spermatocytic Tumours	37

8.3	Sex cord-stromal tumours	37
8.3.1	Leydig cell tumours	38
8.3.2	Sertoli cell tumours	38
8.3.3	Granulosa cell tumour	38
8.3.4	Thecoma/fibroma group of tumours	38
8.3.5	Paratesticular tumours of the epididymis or spermatic cord	38
8.4	Mesothelioma of the tunica vaginalis testis	38
8.5	Follow-up of rare adult para- and testicular cancers	38
9.	REFERENCES	39
10.	CONFLICT OF INTEREST	56
11.	CITATION INFORMATION	56

1. INTRODUCTION

1.1 Aim and objectives

The aim of these guidelines is to present the current evidence for the diagnosis and treatment of patients with cancer of the testis. Testicular cancer (TC) represents 5% of urological tumours affecting mostly younger males. This document addresses post-pubertal testicular germ-cell tumours (TGCTs) in the male including spermatocytic tumour and sex cord/gonadal stromal tumours.

It must be emphasised that clinical guidelines present the best evidence available to the experts, but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and references/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition

The European Association of Urology (EAU) Guidelines Panel on TC consists of a multidisciplinary group of clinicians including, urologists, medical oncologists, a radiation-oncologist, patient representative and a pathologist. When necessary, consultants from other specialties provide input. Members of this Panel have been selected, based on their expertise, to represent the professionals' treating patients with TC. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website: <http://www.uroweb.org/guideline/testicular-cancer/>.

1.3 Available publications

A quick reference document (Pocket guidelines) is available, in print and on the EAU website. These are abridged versions which may require consultation together with the full text version. Several scientific publications are available, as are a number of translations of all versions of the EAU TC Guidelines. All documents are accessible through the EAU website: <https://uroweb.org/guidelines/testicular-cancer>.

1.4 Publication history and summary of changes

1.4.1 Publication history

The EAU published the first guidelines on TC in 2001. Since 2008, the TC Guidelines contains a separate chapter on testicular stromal tumours. The 2024 TC guideline presents a limited update of the 2023 publication. A summary paper of the EAU TC guideline has been published in the society's scientific journal European Urology in 2023 [1].

1.4.2 Summary of changes

For the 2024 Testicular Cancer Guidelines, the key changes incorporated in this publication include:

- A restructure and update of section 5.2 on Imaging of primary tumours and staging;
- An update on the summary of evidence table 6.1.2.5;
- Restructure and rewrite of section 6.2.2 on Metastatic disease (stage IIA/B);
- New recommendation regarding the treatment of metastatic NSGCT with a poor prognosis section 6.3.6.1;
- New section 8.5 on follow-up of rare and adult para- and testicular cancers.

2. METHODS

2.1 Introduction

For the 2024 EAU Guidelines on Testicular Cancer (TC), new and relevant evidence was identified, collated and appraised through a structured assessment of the literature. A broad and comprehensive literature search, covering all sections of the TC Guidelines was performed. The search was limited to studies representing high levels of evidence, i.e. systematic reviews with meta-analysis, randomised controlled trials (RCTs), and prospective non-randomised comparative studies, published in the English language. Databases searched included Medline, EMBASE, and the Cochrane Libraries, covering a time frame between May 1st 2021 and May 1st 2023. A total of 1867 unique records were identified, retrieved and screened for relevance.

Detailed search strategies for the 2024 guideline are available online:
<https://uroweb.org/guidelines/testicular-cancer/publications-appendices>.

Recommendation within the Guidelines are developed by the panels to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences. This decision process, which can be reviewed in the strength rating forms which accompany each guideline statement, addresses a number of key elements:

1. the overall quality of the evidence which exists for the recommendation [2];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact and certainty of patient values and preferences on the intervention.

Strong recommendations typically indicate a high degree of evidence quality and/or a favourable balance of benefit to harm and patient preference. Weak recommendations typically indicate availability of lower quality evidence, and/or equivocal balance between benefit and harm, and uncertainty or variability of patient preference [3].

Additional information can be found in the general Methodology section of this print, and online at the EAU website: www.uroweb.org/guidelines.

A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

2.2 Review

The 2020 Guidelines document was subjected to peer-review following publication. The next peer-review is scheduled for 2025.

2.3 Future goals

- A collaborative systematic review (SR) on hypogonadism following orchidectomy with the EAU Male Sexual Health guidelines panel;
- The development of a TC survivorship plan in collaboration with patient associations;
- Care Pathways on diagnostic, treatment CS I, and treatment of metastatic disease;
- Collaboration with the patient office and patient representatives to develop a care pathway focusing on what the patient needs to know from diagnosis through to follow-up.

3. EPIDEMIOLOGY, AETIOLOGY & PATHOLOGY

3.1 Epidemiology and Aetiology

Testicular cancer represents 1% of adult neoplasms and 5% of urological tumours, with three to ten new cases per 100,000 males/per year in Western societies [4]. The incidence of TC has increased during recent decades, predominantly in industrialised countries [5-8], and it continues to rise. At diagnosis, 1-2% are bilateral and 90-95% of cases are germ cell tumours (GCT) [4]. The peak incidence is in the third decade of life for non-seminomatous germ cell tumour (NSGCT) and mixed GCT patients, and in the fourth decade for seminoma testis (ST) patients. In 5% of GCT patients, the primary site is at an extragonadal location [9].

There are two fundamental categories of GCTs based on their development and epigenetic features. Most malignant post-pubertal GCTs originate from germ cell neoplasia "*in situ*" (GCNIS). Histologically and clinically, these are subdivided into seminomas and non-seminomas, the latter encompassing somatic and extra-embryonal elements of embryonal carcinoma, yolk sac, choriocarcinoma and post-pubertal teratoma [10].

Non GCNIS derived tumours include pre-pubertal type teratoma and yolk sac tumour, which occur in early childhood, and spermatocytic tumours which usually occurs in older men. Although there is overlapping histology between the pre-pubertal type teratoma/yolk sac and the teratoma and yolk sac tumour elements in the GCNIS-derived NSGCT, these have a separate and independent pathogenesis [10].

Risk factors for GCNIS-derived GCTs are components of the testicular dysgenesis syndrome, which encompasses cryptorchidism, hypospadias, decreased spermatogenesis and impaired fertility [11-13] or disorders of sex development [14]. Additional risk factors include a family history of TC among first-degree relatives and the presence of a contralateral testicular tumour or GCNIS [15-23] although the risk was lower if TC patients previously had received platinum-based chemotherapy [24, 25]. Genome-wide association studies revealed detectable susceptibility loci leading to an increased relative risk to develop TC [26].

3.2 Histological classification

General:

The recommended pathological classification shown below is based on the 2022 update of the World Health Organization (WHO) pathological classification [27].

1. Germ cell tumours derived from germ cell neoplasia *in situ*

- Non-invasive germ cell neoplasia
 - Germ cell neoplasia *in situ*
 - Specific forms of intratubular germ cell neoplasia
 - Gonadoblastoma
- The germinoma family of tumours
 - Seminoma
- Non-seminomatous germ cell tumours
 - Embryonal carcinoma
 - Yolk sac tumour, postpubertal-type
 - Choriocarcinoma
 - Placental site trophoblastic tumour
 - Epithelioid trophoblastic tumour
 - Cystic trophoblastic tumour
 - Teratoma, postpubertal-type
 - Teratoma with somatic-type malignancy
- Mixed germ cell tumours of the testis
 - Mixed germ cell tumours
- Germ cell tumours of unknown type
 - Regressed germ cell tumours

2. Germ cell tumours unrelated to germ cell neoplasia *in situ*

- Spermatocytic tumour
- Teratoma, prepubertal-type
- Yolk sac tumour, prepubertal-type
- Testicular neuroendocrine tumour, prepubertal-type
- Mixed teratoma and yolk sac tumour, prepubertal-type

3. Sex cord stromal tumours of the testis

- Leydig cell tumour
 - Leydig cell tumour
- Sertoli cell tumours
 - Sertoli cell tumour
 - Large cell calcifying Sertoli cell tumour
- Granulosa cell tumours
 - Adult granulosa cell tumour
 - Juvenile granulosa cell tumour
- The fibroma thecoma family of tumours
 - Tumours in the fibroma thecoma group
- Mixed and other sex cord stromal tumours
 - Mixed sex cord stromal tumour
 - Signet ring stromal tumour
 - Myoid gonadal stromal tumour
- Sex cord stromal tumour NOS

4. Tumours of the testicular adnexa

- Ovarian-type tumours of the collecting ducts and rete testis
 - Serous cystadenoma
 - Serous tumour of borderline malignancy
 - Serous cystadenocarcinoma
 - Mucinous cystadenoma
 - Mucinous borderline tumour
 - Mucinous cystadenocarcinoma
 - Endometrioid tumours
 - Clear cell adenocarcinoma
 - Brenner tumour
- Tumours of the collecting ducts and rete testis
 - Adenoma of the collecting ducts and rete testis
 - Adenocarcinoma of the collecting ducts and rete testis
- Paratesticular mesothelial tumours
 - Adenomatoid tumour
 - Well-differentiated papillary mesothelial tumour
 - Mesothelioma
- Tumours of the epididymis
 - Cystadenoma of the epididymis
 - Papillary cystadenoma of the epididymis
 - Adenocarcinoma of the epididymis
 - Squamous cell carcinoma of the epididymis
 - Melanotic neuroectodermal tumour of the epididymis

4. STAGING & PROGNOSIS

4.1 Staging

The 2016 Tumour, Node, Metastasis (TNM) classification of the International Union Against Cancer (UICC) is recommended to assess the anatomical extent of the disease (Table 1) [28].

Table 1: TNM classification for testicular cancer (adapted from UICC, 2016, 8th edn.) [28]

pT - Primary Tumour ¹	
pTX	Primary tumour cannot be assessed (see note ¹)
pT0	No evidence of primary tumour (e.g., histological scar in testis)
pTis	Intratubular germ cell neoplasia (carcinoma <i>in situ</i>) ⁺
pT1	Tumour limited to testis and epididymis without vascular/lymphatic invasion; tumour may invade tunica albuginea but not tunica vaginalis*
pT2	Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis**
pT3	Tumour invades spermatic cord with or without vascular/lymphatic invasion**
pT4	Tumour invades scrotum with or without vascular/lymphatic invasion
N - Regional Lymph Nodes – Clinical	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension
N2	Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumour
N3	Metastasis with a lymph node mass more than 5 cm in greatest dimension

Pn - Regional Lymph Nodes – Pathological			
pNX	Regional lymph nodes cannot be assessed		
pN0	No regional lymph node metastasis		
pN1	Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension		
pN2	Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumour		
pN3	Metastasis with a lymph node mass more than 5 cm in greatest dimension		
M - Distant Metastasis			
MX	Distant metastasis cannot be assessed		
M0	No distant metastasis		
M1	Distant metastasis **		
	M1a Non-regional lymph node(s) or lung metastasis		
	M1b Distant metastasis other than non-regional lymph nodes and lung		
S - Serum Tumour Markers (Pre-chemotherapy)			
SX	Serum marker studies not available or not performed		
S0	Serum marker study levels within normal limits		
	LDH (U/l)	hCG (mIU/mL)	AFP (ng/mL)
S1	< 1.5 x N and	< 5,000 and	< 1,000
S2	1.5-10 x N or	5,000-50,000 or	1,000-10,000
S3	> 10 x N or	> 50,000 or	> 10,000

N indicates the upper limit of normal.

LDH = lactate dehydrogenase; hCG = human chorionic gonadotrophin; AFP = alpha-fetoprotein.

¹ Except for pTis and pT4, where radical orchidectomy is not always necessary for classification purposes, the extent of the primary tumour is assessed in the radical orchidectomy specimen; see pT. In other circumstances, TX is used if no radical orchidectomy has been performed.

* The current "Carcinoma in situ" nomenclature is replaced by GCNIS.

* AJCC eighth edition subdivides T1 Pure Seminoma by T1a and T1b depending on size no greater than 3 cm or greater than 3 cm in greatest dimension [29].

** AJCC eighth edition considers hilar soft tissue invasion and epididymal invasion as pT2, while the discontinuous involvement of the spermatic cord is considered as pM1 [29].

4.2 The Union for International Cancer Control prognostic groups

According to the 2016 TNM classification, the following prognostic groups are defined:

Table 2: Prognostic groups for testicular cancer (UICC, 2016, 8th edn.) [28]

Stage grouping	T	N	M	S
Stage 0	pTis	N0	M0	S0
Stage I	pT1-T4	N0	M0	SX
Stage IA	pT1	N0	M0	S0
Stage IB	pT2 - pT4	N0	M0	S0
Stage IS	Any pT/TX	N0	M0	S1-3
Stage II	Any pT/TX	N1-N3	M0	SX
Stage IIA	Any pT/TX	N1	M0	S0
	Any pT/TX	N1	M0	S1
Stage IIB	Any pT/TX	N2	M0	S0
	Any pT/TX	N2	M0	S1
Stage IIC	Any pT/TX	N3	M0	S0
	Any pT/TX	N3	M0	S1

Stage III	Any pT/TX	Any N	M1a	SX
Stage IIIA	Any pT/TX	Any N	M1a	S0
	Any pT/TX	Any N	M1a	S1
Stage IIIB	Any pT/TX	N1-N3	M0	S2
	Any pT/TX	Any N	M1a	S2
Stage IIIC	Any pT/TX	N1-N3	M0	S3
	Any pT/TX	Any N	M1a	S3
	Any pT/TX	Any N	M1b	Any S

Stage IA: Primary tumours limited to the testis and epididymis, with no evidence of microscopic vascular or lymphatic invasion by tumour cells on microscopy, no sign of metastases on clinical examination or imaging, and post-orchidectomy serum tumour marker levels within normal limits. Marker decline in patients with Clinical Stage I (CS I) disease should be assessed until normalisation occurs on two consecutive measurements.

Stage IB: More locally invasive primary tumour, but no sign of metastatic disease.

Stage IS: Following orchidectomy tumour markers increase, remain persistently elevated or fail to decline as expected by half-lives indicating the presence of subclinical metastatic disease. The presence of a second GCT in the contralateral testis should also be excluded.

In population-based patient series from developed countries, 75-80% of SGCT patients, and 55-64% of NSGCT patients had CS I disease at diagnosis [30, 31]. True CS I, i.e. persistently elevated or increasing serum tumour marker levels after radical orchidectomy, was found in approximately 5% of NSGCT patients [30].

4.3 Risk factors for relapse in clinical stage I testicular cancer

For CS I seminoma germ cell tumour (SGCT), primary tumour size and stromal invasion of the rete testis have been identified to be associated with relapse risk in a pooled analysis of retrospective data [32]. Absence of both factors was associated with a low risk of recurrence (6%) [35]. Whilst the original analysis was not supported by a subsequent retrospective report [33], some prospective series [34-36] have supported the prognostic significance of tumour size and stromal invasion of the rete testis. Two SRs assessed the prognostic value of both risk factors [37, 38]. While tumour size (continuous or dichotomised) and rete testis invasion were associated with a higher risk of relapse, both SRs highlighted the low quality of the studies included and concluded that the level of evidence was too low to be able to recommend the use of both risk factors to drive adjuvant treatment decisions [37, 38].

For CS I NSGCT, invasion of the primary tumour into blood or lymphatic vessels, (i.e. lymphovascular invasion (LVI)), was strongly associated with the risk of relapse disease [39-41]. No other risk factors have the same level of validation for prognostic significance [42]. While interobserver agreement is variable, immunohistochemistry with vascular markers may improve detection of LVI [43]. The percentage of embryonal carcinoma within a tumour may enhance the positive predictive value (PPV) and negative predictive value (NPV) of LVI [40], but there is no definitive prognostic cut-off for percentage [40]. Risk of relapse at five years according to historical figures, for patients with LVI-positive tumours was 50% vs. 15% in patients with LVI-negative tumours.

Table 3: Pathological risk-factors for occult metastatic disease in clinical stage I testicular cancer

Histological type	Seminoma [37]	Non-seminoma [41, 44]
• Pathological risk-factors	• Tumour size • Invasion of the rete testis	• Lympho-vascular invasion in peri-tumoral tissue

4.4 The International Germ Cell Cancer Collaborative Group (IGCCCG) classification for the prognostic risk groups of metastatic germ cell cancer

The 1997 IGCCCG defined a prognostic risk-factor system for metastatic GCT based on identification of clinically independent adverse factors [45]. The classification has been revalidated on a contemporary cohort of metastatic TGCT treated with cisplatin/etoposide based first-line chemotherapy [46].

Compared to the 1997 figures, the five-year progression-free survival (PFS) of NSGCT patients was unchanged for good- and intermediate-risk, but significantly improved for poor-risk patients (from 41% to 54%). The five-year overall survival (OS) was substantially better for all groups. In addition to the traditional components of the IGCCCG risk-prognostic groups previously described, older age (linear association) and lung metastases were confirmed as negative factors for PFS [46].

For SGCT, revalidation of the IGCCCG classification showed that the five-year PFS increased to 89% and 79% in good- and intermediate-risk patients with corresponding OS rates of 95% and 88%. Testicular lactate dehydrogenase (LDH) over 2.5 times the upper limit of normal (ULN) was identified as a possible adverse prognostic factor in regard to reduced three-year PFS, however overall three-year survival was not affected [47].

Table 4: Prognostic-based staging system for metastatic germ cell cancer (IGCCCG) [46, 47]*

Good-prognosis group	
NSGCT 5-year PFS 90% 5-year survival 96%	<i>All of the following criteria:</i> <ul style="list-style-type: none"> • Testis/retro-peritoneal primary • No non-pulmonary visceral metastases • AFP < 1,000 ng/mL • β-hCG < 5,000 IU/L (1,000 ng/mL) • LDH < 1.5 x ULN
SGTC 5-year PFS 89% 5-year survival 95%	<i>All of the following criteria:</i> <ul style="list-style-type: none"> • Any primary site • No non-pulmonary visceral metastases • Normal AFP • Any β-hCG • Any LDH
Intermediate-prognosis group	
NSGCT 5-year PFS 78% 5-year survival 89%	<i>Any of the following criteria:</i> <ul style="list-style-type: none"> • Testis/retro-peritoneal primary • No non-pulmonary visceral metastases • AFP 1,000 - 10,000 ng/mL or • β-hCG 5,000 - 50,000 IU/L or • LDH 1.5 - 10 x ULN
SGCT 5-year PFS 79% 5-year survival 88%	<i>All of the following criteria:</i> <ul style="list-style-type: none"> • Any primary site • Non-pulmonary visceral metastases • Normal AFP • Any β-hCG • Any LDH
Poor-prognosis group	
NSGCT 5-year PFS 54% 5-year survival 67%	<i>Any of the following criteria:</i> <ul style="list-style-type: none"> • Mediastinal primary • Non-pulmonary visceral metastases • AFP > 10,000 ng/mL or • β-hCG > 50,000 IU/L (10,000 ng/mL) or • LDH > 10 x ULN
SGCT	No patients classified as poor-prognosis

* Pre-chemotherapy serum tumour markers should be assessed immediately prior to the administration of chemotherapy (same day).

AFP = alpha-fetoprotein; β -hCG = human chorionic gonadotrophin; LDH = lactate dehydrogenase; PFS = progression-free survival.

5. DIAGNOSTIC EVALUATION

5.1 Physical examination

Testicular cancer usually presents as a painless testicular mass or incidental finding on ultrasound (US). Pain, either scrotal or abdominal/back, may occur and result in delayed diagnosis [48]. Gynaecomastia may be present in a small number of patients. Clinical assessment should thus include abdominal, chest and supraclavicular examination.

5.2 Imaging

5.2.1 Primary tumour

The primary tumour and contralateral testis need to be assessed radiologically to

1. confirm the presence of a mass;
2. determine whether it is intra- or extra-testicular;
3. assess its volume and anatomical location;
4. characterise the contralateral testicle – to exclude other lesions and identify risk factors for GCNIS (see section 5.4.4).

High-frequency (>10 MHz) testicular US is recommended. Scrotal US is also recommended for all men with retroperitoneal or visceral masses with/without elevated serum β -hCG or Alpha-fetoprotein (AFP) in the absence of a palpable testicular mass [49].

Small, usually non-palpable masses may be incidental findings on scrotal US which may be benign. Of lesions with small diameter virtually all < 3mm, 87% of those < 5mm and 70% < 10mm are benign [50-52]. With small masses US features may assist in discriminating between benign and malignant tumours although none are completely reliable [50].

Scrotal magnetic resonance imaging (MRI) provides higher sensitivity and specificity than US in the diagnosis of TC, but its high cost does not justify its routine use for this purpose [53]. It should only be considered when US is inconclusive as local staging for potential testis-sparing surgery (TSS), to differentiate between paratesticular and intratesticular lesions, and/or to characterise intratesticular masses (e.g., distinctive features of Leydig tumours) [53].

5.2.2 Staging

Cross-sectional imaging of the chest, abdomen and pelvis is recommended in patients with elevated markers or clinical suspicion of metastases for staging before orchidectomy and remains standard practice. This may be postponed in patients with small or indeterminate masses until histopathological confirmation of malignancy. Contrast enhanced CT scan (CECT) and MRI are the imaging modalities used. Evidence does not support the use of Fluorodeoxyglucose-positron emission tomography (FDG-PET) for initial staging of TC [54, 55].

a. Abdomen and Pelvis

Contrast enhanced CT scan is the long-established imaging modality used to assess the abdomen and pelvis to identify nodal and visceral metastases. The size of metastases should be described in three dimensions, or at least by the greatest diameter. The expected patterns of nodal spread in TC should be considered when evaluating small and borderline nodes.

A SR of a number of small studies, with a total of 102 evaluable patients, has suggested that MRI appears comparable to CECT in detecting nodal metastases [56]. It is significantly more expensive and less available than CECT for routine use. It clearly has utility in patients who have contra-indications to iodine-based contrast media or likely to require numerous subsequent scans.

b. Thorax

The chest and supraclavicular fossa should also be imaged with CECT to assess for nodal and pulmonary disease. Magnetic resonance imaging appears equivalent to CT in detecting supra-diaphragmatic lymph nodes but less sensitive in detecting pulmonary nodules. Thus, it is not recommended as a routine alternative to CT [57].

c. **Other Sites**

Cerebral and spinal imaging is recommended in GCT patients with either multiple lung metastases or poor-prognosis IGCCCG risk group (especially with β -hCG values > 5,000 UI/L), or clinical symptoms [58]. Data from cerebral and spinal metastasis detection in other malignancies suggest that MRI is far more sensitive than CECT but requires specific expertise [59, 60]. When available, MRI should be used to evaluate for both cerebral and spinal metastases in GCTs if there are clinical concerns. Contrast enhanced computerised tomography may be used if MRI is not available or contraindicated.

5.3 Serum tumour markers

5.3.1 Pre-operative serum tumour markers

Serum AFP, beta subunit of human Chorionic Gonadotropin (β -hCG) and LDH should be determined before orchidectomy as they support the diagnosis of TC and may be indicative of GCT histology.

Up to 90% of NSGCT's have elevated AFP or β -hCG at diagnosis with 39% having an increased level of both [48, 61]. Pure seminomas may also have elevated β -hCG level at diagnosis in up to 30% of cases [61]. Significant elevation of AFP in patients with seminomas should raise concerns of a NSGCT component. Modest stable marker elevations may be considered 'normal' and of no clinical significance [45].

Thus, current tumour markers have limitations due to their low sensitivity as normal levels do not exclude the presence of disease.

5.3.2 Serum tumour markers after orchidectomy

Tumour markers need to be repeated following orchidectomy providing staging and prognostic information [45]. If elevated pre-operatively normalisation may take several weeks as the serum half-lives of AFP and β -hCG are five to seven days and one to three days respectively. If these remain elevated or increase metastatic disease is likely [61]. Marker normalisation after orchidectomy however does not exclude the possibility of metastatic disease.

In addition to staging marker levels are used to define risk stratification and prognosis (Table 4). They are also used to monitor treatment response and detect disease relapse [61]. With follow-up the precise frequency of testing is not well defined [62].

5.3.3 Other tumour markers

Micro RNAs (miRNAs) are emerging as potential new biomarkers. Pre-operative elevation has been reported in 80-90% of both SGCT and NSGCT with higher levels in metastatic compared to localised disease [63]. A number of studies suggest higher discriminatory accuracy for micro-RNA (miRNAs) (particularly miR-371a-3p) compared to conventional GCT markers in diagnosis, clinical staging, treatment monitoring, and predicting of residual or recurrent viable disease [63-65]. Furthermore, they may differentiate between GCT and other (stromal/non-germ cell originated) tumours [65]. Issues which need to be resolved for use in routine clinical practice include laboratory standardisation, availability of the test and, importantly, prognostic validation [66]. As with both AFP and β -hCG miRNA is not expressed in teratoma which will limit its use in NSGCT.

5.4 Inguinal exploration and initial management

5.4.1 Orchidectomy

Orchidectomy including division of the spermatic cord at the internal inguinal ring represents the standard of care for patients with a TGTC. A scrotal approach should be avoided when TC is suspected as it results in a higher local recurrence rate [67].

5.4.2 Testis-sparing surgery

In men with GCTs, orchidectomy represents the standard of care as pathological studies describe multifocal and/or adjacent GCNIS in 20-30% of patients [68]. Testis sparing surgery when feasible, may be considered in synchronous bilateral tumours or in tumours in solitary testis [69]. In these settings, at least two additional testicular biopsies should be taken to exclude GCNIS [70].

Testis-sparing surgery (TSS) is a valid treatment option in men with interstitial cell or benign testicular tumours and may prevent hypogonadism and infertility in young men. These tumours are often small although larger lesions may be difficult to differentiate from GCT.

Thus, TSS may be considered in patients with small or indeterminate testicular masses, negative tumour markers and a normal contralateral testis to avoid over-treatment of potentially benign lesions and preserve testicular function [69, 71]. Patients should be informed that cancer may be present even in small (i.e., < 1 cm) masses [69, 72, 73].

In both settings, TSS should be offered together with frozen section examination (FSE). Frozen section examination has shown to be reliable and highly concordant with final histopathology in expert hands, with a 99% and 96% of sensitivity and specificity respectively and 98% and 97% of PPV and NPV, respectively [71]. In cases of discordance between FSE and final pathology delayed orchiectomy may be required.

In cases of a history of GCT or indeterminate small testicular lesion, patients should be made aware of the following issues regarding TSS practice: that limited data exists regarding oncological safety of TSS; that local recurrence rates have been reported (up to 26.9%), when TC is present in the specimen [69, 74] and that TSS has implications for ongoing surveillance of the testis. Similarly, patients should be informed about the role and impact of adjuvant radiotherapy when GCNIS is present, potential infertility, the need for hormonal supplementation despite parenchyma preservation [69, 75] and that discordance between FSE and final pathology requiring a delayed orchidectomy.

5.4.3 **Insertion of testicular prosthesis**

Testicular prosthesis should be offered to all patients receiving unilateral or bilateral orchidectomy [76]. The prosthesis can be inserted at orchidectomy or subsequently without adverse consequences, including infection [77].

5.4.4 **Contralateral biopsy**

Contralateral biopsy has been advocated to exclude GCNIS [78] and routine policy in some countries [79]. It is, however, controversial to recommend routine contralateral biopsy in all patients due to the low incidence of GCNIS and metachronous contralateral testicular tumours (up to 9% and approximately 2.5%, respectively) [80, 81], the morbidity of GCNIS treatment (see section 6.1.1), and the fact that most metachronous tumours are low stage at presentation [82, 83]. Nevertheless, the risks and benefits of biopsy of the contralateral testis should be discussed with TC patients at high risk for contralateral GCNIS, i.e., testicular volume < 12 mL, and/or a history of cryptorchidism. Contralateral biopsy is not necessary in patients > 40 years without risk factors [70, 84, 85]. Patients should be informed that a subsequent GCT may arise despite a negative biopsy [86]. When indicated, a two-site surgical testicular biopsy is the technical procedure recommended [70].

5.5 **Pathological examination of the testis**

The recommendations for reporting and handling the pathological examination of a testis neoplasm are based on the recommendations of the International Society of Urological Pathology (ISUP) [39, 44, 87, 88].

Mandatory pathological requirements:

- **Macroscopic features:** It must indicate radical or partial orchidectomy, side, testis size, number of tumours, and macroscopic features of the epididymis, cord length, and tunica vaginalis.
- **Sampling:** At least a 1 cm² section for every centimetre of maximum tumour diameter including normal macroscopic parenchyma (if present), tunica albuginea and epididymis, with selection of suspicious areas. If the tumour is < 20 mm it should be completely sampled.
- At least one proximal (base of the cord) and one distal section of spermatic cord plus any suspicious area. Cord blocks should preferably be taken prior to tumour sections to avoid contamination.
- **Microscopic features and diagnosis:** Histological types (specify individual components and estimate amount as percentage) according to WHO 2022 [27]:
 - Presence or absence of peri-tumoral lymph and/or blood vessel invasion. In case of doubt, the use of endothelial markers, such as CD31, are recommended.
 - Presence or absence of GCNIS in non-tumour parenchyma.
 - In case of rete testis invasion attention should be paid to distinguishing between pagetoid involvement and stromal invasion [44].
- If microscopic findings are not concordant with serum markers further block samples should be taken.
- Pathological tumour (pT) category according to TNM 2016 [28]. In a multifocal seminoma the largest nodule should be used to determinate pT category.

Immune-histochemical markers in cases of doubt are:

- Seminoma: CD-117 (c-KIT), OCT 3/4, Sall4, PLAP
- GCNIS: CD-117 (c-KIT), OCT 3 / 4, Sall4, PLAP
- Syncytiotrophoblastic: β -hCG
- Embryonal carcinoma: CD30
- Yolk sac tumour: Glypican 3, AFP.
- Sex cord gonadal tumours: Inhibin, calretinin steroidogenic factor 1.

The search for i12p (FISH or PCR) or gain in Chr9 (spermatocytic tumour) are additional molecular techniques which are only rarely required. Confirmation of the utility of other molecular markers such as P53, MDM2, KRAS and HRAS is awaited [89].

In order to facilitate consistent and accurate data collection, promote research, and improve patient care, the International Collaboration on Cancer Reporting has constructed a dataset for the reporting of urological neoplasms. The dataset for testicular tumours encompasses the updated 2016 WHO classification of urological tumours, the ISUP consultation and staging with the 8th edition of the American Joint Cancer Committee (AJCC) [88].

The dataset includes those elements unanimously agreed by the expert panel as “required” (mandatory) and those “recommended” (non-mandatory) that would ideally be included but are either non-validated or not regularly used in patient management [88]. The dataset for handling pathological assessment of TC is shown in Table 5.

Table 5: Recommended dataset for reporting of neoplasia of the testis (modified from the International Collaboration on Cancer Reporting) [88]

Elements	Required	Recommended*	Content	Remarks
Clinical information		√	- Not provided - Previous history of testicular cancer - Previous therapy - Other	Specify each
Serum tumour markers		√	- Not provided - If provided within normal limits or - Specify serum tumour markers used - Specify levels - Specify date markers were drawn	Select all that apply: Serum tumour markers: LDH (IU/L), AFP (ug/L), β -hCG (IU/L)
Operative procedure	√		- Not specified - Orchiectomy partial - Orchiectomy radical - Other	Specify side for partial or radical orchiectomy. Specify other
Tumour focality	√		- Cannot be assessed - Indeterminate - Unifocal - Multifocal	If multifocal specify number of tumours in specimen.
Maximum tumour dimension	√		- Cannot be assessed - Dimensions largest tumour (mm) - Dimensions additional tumour nodules [#]	Specify at least maximum diameter of largest tumour. Preferably specified 3 dimensions/axes. [#]

Macroscopic extent of invasion	√		<ul style="list-style-type: none"> - Cannot be assessed - Confined to testis - Invades epididymis - Invades tunica vaginalis - Invades hilar structures - Invades spermatic cord - Invades scrotum - Other 	Select all that apply. If other specify.
Block identification key		√	N/A	List overleaf or separately with indication of nature and origin of all tissue blocks.
Histological tumour type	√		<ul style="list-style-type: none"> - Germ cell tumour: type and percentage - Other 	Use WHO classification (2022) update [27]. If other specify.
Microscopic extent of invasion	√		<ul style="list-style-type: none"> - Rete testis of stromal/ interstitial type - Epididymis - Hilar fat - Tunica albuginea[#] - Tunica vaginalis - Spermatic cord - Scrotal wall 	For all: <ul style="list-style-type: none"> - not submitted - not involved - involved
Lymphovascular extension	√		<ul style="list-style-type: none"> - Not identified - Present 	If present specify type. [#]
Intratubular lesions (GCNIS)	√		<ul style="list-style-type: none"> - Not identified - Present - Other intratubular lesions[#] 	If other intratubular lesions present identify type. [#]
Margin status	√		<ul style="list-style-type: none"> - Partial orchidectomy: <ul style="list-style-type: none"> . cannot be assessed . involved . not involved - Radical orchidectomy: <ul style="list-style-type: none"> . cannot be assessed . spermatic cord margin involved . spermatic cord margin not involved - Other margin involved 	In partial orchidectomy if margin not involved, distance of tumour from closest margin (mm). [#] If other margin involved specify.
Coexisting pathology		√	<ul style="list-style-type: none"> - None identified - Hemosiderin-laden macrophages - Atrophy - Other 	If other specify
Ancillary studies		√	<ul style="list-style-type: none"> - Not performed - Performed 	If performed specify
Response to neoadjuvant therapy		√	<ul style="list-style-type: none"> - Present - Absent - No prior treatment - Cannot be assessed 	Explain reasons if cannot be assessed.
Pathologic staging*	√		T classification according to TNM 8 th edition (UICC)**	m-multiple primary tumours r-recurrent y-post-therapy

* Not mandatory. Ideally to be included but either non-validated or no regularly used in patient management.

** TNM 8th edition (AJCC) used in the original publication.

Recommended, i.p. intratubular seminoma and embryonal carcinoma.

5.6 Screening

No high-level evidence studies supporting screening programs exists [90, 91]. In contrast young males should be informed about the importance of testicular self-examination. Testicular self-examination is recommended in high-risk groups which include a history of cryptorchidism, as well as those with a personal or family history of TC [90, 92].

5.7 Summary of evidence and recommendations for the diagnosis and staging of Testicular Cancer

Summary of evidence	LE
Poor sperm quality is frequently found in TC patients, before and after treatment. Semen preservation is the most cost-effective strategy for fertility preservation.	2b
Serum tumour markers (AFP, β -hCG and LDH) should be determined before and after orchidectomy and throughout follow-up. They are used for accurate staging, risk stratification, to monitor treatment and to detect relapse.	2b
For abdominal staging, CECT has a median sensitivity, specificity, PPV, NPV and accuracy of 67%, 95%, 87%, 73% and 83%, respectively. Sensitivity decreases and specificity increases with increasing lymph node size.	2a
For chest staging, CECT has a median sensitivity, specificity, PPV, NPV and accuracy of 100%, 93%, 68%, 100% and 93%, respectively.	2a
Magnetic resonance imaging and CECT are key image modalities for the detection of brain metastasis. Magnetic resonance imaging is far more sensitive than CECT, though it does require expertise.	2b
Fluorodeoxyglucose-positron emission tomography has a limited diagnostic accuracy for staging before chemotherapy.	2b
There are no high-level evidence studies supporting screening programs.	2b
In testicular sparing surgery, FSE has shown to be reliable and highly concordant with final histopathology.	1b
There is no evidence supporting any size criteria for a testicular lesion to be safely followed-up.	2b
In patients without risk factors, there is low incidence of contralateral GCNIS and of metachronous GCT.	2b

Recommendations	Strength rating
Discuss sperm banking with all men prior to starting treatment for testicular cancer (TC).	Strong
Perform bilateral testicular ultrasound (US) in all patients with suspicion of TC.	Strong
Perform physical examination including supraclavicular, cervical, axillar, and inguinal lymph nodes, breast, and testicles.	Strong
Measure serum tumour markers both before and after orchidectomy taking into account half-life kinetics.	Strong
Perform orchidectomy and pathological examination of the testis to confirm the diagnosis and to define the local extension (pathological tumour (pT) category). In a life-threatening situation due to extensive metastasis, commence chemotherapy prior to orchidectomy.	Strong
Perform contrast enhanced computerised tomography (CECT) scan (chest, abdomen, and pelvis) in patients with a diagnosis of TC. In case of iodine allergy or other limiting factors perform abdominal and pelvic magnetic resonance imaging (MRI).	Strong
Perform MRI of the brain (or brain CECT if not available) in patients with multiple lung metastases, or high beta subunit of human Chorionic Gonadotropin (β -hCG) values, or those in the poor-prognosis International Germ Cell Cancer Collaborative Group (IGCCCG) risk group.	Strong
Do not use positron emission tomography-computed tomography or bone scan for staging.	Strong
Encourage patients with TC to perform self-examination and to inform first-degree male relatives of the need for self-examination.	Weak
Discuss testis-sparing surgery with frozen section examination in patients with a high likelihood of having a benign testicular tumour which are suitable for enucleation.	Strong
Discuss biopsy of the contralateral testis to patients with TC and who are at high-risk for contralateral germ cell neoplasia "in situ".	Strong

6. DISEASE MANAGEMENT

6.1 Stage I germ cell tumours

6.1.1 *Germ cell neoplasia "in situ" (GCNIS)*

If GCNIS is diagnosed and the contralateral testis is normal, options include orchidectomy or close observation, as the five-year risk of developing TC is 50% [93]. In a solitary testis, local radiotherapy (18-20 Gy in fractions of 2 Gy) should be considered [94-97]. Radiotherapy to a solitary testis will result in infertility and increased long-term risk of Leydig cell insufficiency [94]. Fertile patients who wish to father children may defer radiation therapy and be monitored with regular testicular US [70].

Chemotherapy is ineffective to reliably irradiate GCNIS [98, 99].

6.1.2 *Seminoma germ cell tumour clinical stage I*

Up to 20% of CS I SGCT patients have subclinical metastatic disease, usually in the retroperitoneum, and will relapse after orchidectomy alone [100, 101]. Adjuvant treatment decisions should be based on thorough discussions with the patient, incorporating potential risks and benefits, as well as individual patient circumstances, as 80% of unselected CS I SGCT patients are cured by orchidectomy alone. Regardless of management, survival in CS I disease is almost 100% [102].

6.1.2.1 *Surveillance*

This requires a strict protocol of repeated cross-sectional imaging, monitoring of serum tumour markers and clinical assessment for the early identification of patients experiencing relapse who must receive salvage treatment (See Table 11).

Several prospective, non-randomised surveillance studies have been conducted over the past decade. These have shown an overall risk of relapse in unselected CS I patients of 12-20% at five years with 17% in the largest series of over 1,500 patients [103]. Most occur in the retroperitoneum during the first two years [104, 105].

According to a SR, active surveillance offers almost identical overall survival as adjuvant management strategies, approaching 100% [102].

The cancer-specific survival (CSS) rate on "active surveillance" (AS) for CS I seminoma is over 99% [103, 105, 106]. Whilst cost effective compared to other management strategies [107], surveillance can represent a burden to the patient due to the need for repeated imaging of the retroperitoneum and clinic visits. These may negatively impact patient compliance which is crucial to an active surveillance strategy.

6.1.2.2 *Adjuvant chemotherapy*

An RCT comparing one cycle of carboplatin reaching area under curve of 7 mg/mL/min (AUC 7) to adjuvant radiotherapy (RT) showed no difference in relapse-free rates (95% and 96%), time to recurrence and survival after a median follow-up of four years [108]. Adjuvant carboplatin (AUC 7) is therefore an alternative to RT or surveillance in CS I SGCT [108]. Time to relapse after Carboplatin may be longer than with AS, as retrospective data reported a median time to relapse of nineteen months, with 15% of relapses occurring beyond three years. Most patients relapsing after adjuvant carboplatin can be successfully treated by standard, stage-adapted cisplatin-based chemotherapy [109]. In some selected cases, retroperitoneal lymph-node dissection may be adopted in specific protocols (see below).

One cycle of adjuvant carboplatin does not seem to have significant long-term toxicities. In a series of 199 CS I SGCT patients, there was no increase in overall mortality, mortality from cardiovascular events and no excess of haematological or non-testicular solid malignancies compared to the general population in the UK [110].

6.1.2.3 *Adjuvant radiotherapy*

Radiotherapy should generally be reserved for a highly selective group of patients, who would be unsuitable for systemic chemotherapy in the event of relapse. This relates to the toxicity of RT, specifically the long-term risk of non-germ cell malignancies in the radiation field [111-114]. Generally, adjuvant RT should be avoided, particularly in young patients with a long life expectancy.

Risk-adapted treatment

Prospective trials based on tumour size > 4 cm and stromal rete testis invasion have demonstrated the feasibility of a risk-adapted approach [33-36, 115].

A trial of 897 patients offered surveillance to patients with no or one of these two risk factors whilst patients with both risk factors were offered one dose of carboplatin, AUC 7 [36]. At a median follow-up of 5.6 years, the patients without risk factors, 4% of surveillance relapsed compared to 2% after adjuvant carboplatin. With one or both risk factors 15.5% of surveillance patients relapsed vs. 9% receiving adjuvant carboplatin. Thirty-three per cent of relapses after adjuvant carboplatin occurred more than three years after orchidectomy with 3% occurring after five years [36].

6.1.2.4 *Summary of evidence and recommendations for the treatment of clinical stage I seminoma germ cell tumour of the testis*

Summary of evidence	LE
Patients with CS I SGCT have, in general, a low risk of recurrence	2a
A combination of tumour size category and rete testis invasion correlate with the risk of relapse at 5 years.	2a
Evidence and ease of use are limited for a routine use in guiding adjuvant treatment decisions upon risk factors.	2a
Active surveillance is a feasible approach with conditional relapse risk in unselected series of between 12-20%. Disease-free survival approaches 100% independently of treatment.	2a
In patients without conventional risk factors (tumour size < 4 cm and no rete testis invasion), the five-year relapse rate under surveillance is up to 6-8%, respectively; whereas in the presence of one or two risk factors, five-year relapse rate in contemporary surveillance series is 15-20%.	2b
In non-randomised prospective series five-year relapse rates with adjuvant carboplatin are 2% in patients without conventional risk factors and 9% in patients with one or both risk factors.	2b
Adjuvant chemotherapy with one course carboplatin AUC 7 is not inferior to adjuvant radiotherapy when pathological risk factors are considered. Relapse rates with both adjuvant treatments are around 5%.	1b
Adjuvant radiotherapy is associated with an increased risk of developing secondary non-germ cell malignancies.	2b

Recommendations	Strength rating
Fully inform the patient about all available management options, including surveillance or adjuvant therapy after orchidectomy, as well as treatment-specific recurrence rates and acute and long-term side effects.	Strong
Offer surveillance as the preferred management option if resources are available and the patient is compliant.	Strong
Offer one dose of carboplatin at area under curve 7 if adjuvant chemotherapy is considered.	Strong
Do not perform adjuvant treatment in patients at very low risk of recurrence (no risk factors).	Strong
Do not routinely perform adjuvant radiotherapy.	Strong
Adjuvant radiotherapy should be reserved only for highly selected patients not suitable for surveillance and with contraindication for chemotherapy.	Strong

6.1.3 ***Non-seminomatous germ cell tumours clinical stage I***

Management options for CS I NSGCTs include surveillance and adjuvant chemotherapy. Retroperitoneal lymph node dissection has a limited role.

Overall, approximately 70% of CS I NSGCTs are cured with orchidectomy alone. In those with the high-risk feature of LVI, historical figures reported relapse in 50% compared to 15% in those without LVI. A thorough discussion should be undertaken with the patient outlining the potential advantages and disadvantages of treatment options, as well as individual co-morbidities, disease features, risk factors, specific circumstances, and personal preferences, to guide their treatment decision.

6.1.3.1 Surveillance

Surveillance for CS I NSGCT entails a strict protocol of repeated cross-sectional imaging, monitoring of serum tumour markers and clinical assessment for the early identification of patients experiencing relapse who must receive salvage treatment (See Table 11).

The largest reports of surveillance indicate a cumulative relapse risk in about 30% of CS I NSGCT (five-year conditional risk of relapse 42% and 17% for high- and low-risk CS I-NSGCT, respectively) [101, 103]. Of these, 92% present within the first two years [101, 103, 116-118].

6.1.3.2 Retroperitoneal lymph node dissection

Since the introduction of cisplatin-based chemotherapy the role of adjuvant primary retroperitoneal lymph node dissection (RPLND) in men with CS I NSGCTs has decreased. According to data from high-volume and expert centres, primary RPLND is associated with a risk of relapse < 15% [119]. More recent data report on a relapse rate of 10% in case of negative nodes (pathologic stage (PS) – I) and < 30% in case of nodal metastases (PS II) [119-121], possibly due to selection or stage migration.

The few indications in CS I disease include men with teratoma with somatic malignant component, or patients who are not willing or suitable to undergo chemotherapy in case of recurrence, in particular in those when vascular invasion is present.

Recent publication supports the safety of surveillance alone, in PS II disease following RPLND, as 75-80% are relapse free at two and five years [120-122]. Those with relapse can be rescued with standard chemotherapy [123, 124]. With PS II, both adjuvant chemotherapy comprising two cycles of (B)EP (except for cases of ppt (post pubertal teratoma) only) and AS are standard option to be discussed with each individual.

Strategies to reduce the morbidity of primary RPLND include nerve-sparing and minimally invasive approaches. In a multi-centre setting, higher rates of in-field recurrences and complications have been reported with nerve-sparing RPLND [125, 126]. This suggests that primary RPLND, when indicated and chosen, should be performed by an experienced surgeon in a specialist centre. Minimally invasive (laparoscopic or robot-assisted) primary RPLND, appears feasible and safe (e.g., low-complication rate) in experienced hands. This must only be performed in high-volume RPLND centres with appropriate minimal-invasive surgery expertise [127-134]. There is limited recent data on mid-term follow-up.

Despite some advantages, including good efficacy, a less-demanding and costly follow-up due to the reduced need for cross-sectional imaging [135], RPLND for CS I NSGCT has diminished its role in view of the high CSS rates of surveillance, the low relapse rates with adjuvant chemotherapy, and the lower reproducibility of primary RPLND on a large scale.

6.1.3.3 Adjuvant chemotherapy

Adjuvant chemotherapy has been evaluated with both one and two cycles of BEP (cisplatin, etoposide, bleomycin) in CS I NSGCT. A prospective trial from 1996, as well as subsequent studies, used two cycles of BEP in high-risk patients (LVI present) [136-138]. In these series, including 200 patients, some with a median follow-up of nearly 7.9 years [136], a relapse rate of only 2.7% was reported, with minimal long-term toxicity. Two cycles of cisplatin-based adjuvant chemotherapy do not appear to adversely affect fertility or sexual activity [139].

Other studies have shown one cycle of adjuvant BEP results in similar very low recurrence rates (2-3%) [140, 141]. Reduction from two to one cycle of BEP improves the risk-benefit ratio of adjuvant chemotherapy considerably. A randomised phase III trial has also compared two-year recurrence free survival with adjuvant BEP x 1 to RPLND. Results favoured chemotherapy with recurrence free survival of 99.5% vs. 91% [126]. No clinically relevant differences in quality of life (QoL) were detected [142].

A community based prospective study of 490 unselected patients with CS I NSGCT that received adjuvant single cycle BEP had five-year relapse rates of 3% and 2% for LVI+ and LV- patients, respectively. After a median follow-up of eight years these rates were sustained, no relapses were observed beyond 3.3 years [140, 141]. These numbers imply that > 90% of relapses are prevented by single cycle BEP which is now the recommended strategy if adjuvant chemotherapy is considered [140, 141]. The very-long term (> 20 years) side effects of adjuvant chemotherapy, particularly cardiovascular, are yet to be fully defined and this should be considered during shared decision-making [143, 144].

Limited data are available on outcomes with relapse after adjuvant BEP. A retrospective analysis indicated that about one third of these relapses were late and that the outcome may be slightly worse compared to those presenting with *de novo* metastatic disease [145].

6.1.3.4 Risk-adapted treatment

A risk-adapted strategy is an alternative to any single approach for patients with CS I NSGCT. The advantages and disadvantages of treatment options must be discussed with patients in the context of their specific circumstances including disease risk factors, co-morbidities, and personal preference, as well as clinician recommendation in reaching a treatment decision. Lympho-vascular invasion is the strongest and most reproducible predictive factor for relapse and should be carefully outlined to the patient to assist in their decision-making.

Patients without LVI should be guided to consider surveillance, although some patients with significant co-morbidities or concerns regarding salvage chemotherapy with multicycle cisplatin-based chemotherapy may opt for adjuvant therapy. Those with LVI should have their high risk of relapse (up to 50%) highlighted and be guided to consider adjuvant management, and chemotherapy with BEP X 1 as the “preferred” option.

Some patients may wish to consider primary RPLND although they need to be aware of the potential additional requirement of adjuvant chemotherapy if nodes contain active disease (pN1), as well as the 10% risk of systemic relapse, even if pN0, requiring subsequent chemotherapy treatment (BEP X 3).

6.1.3.5 Post-pubertal teratoma with somatic malignant component

A multi-institutional study analysing retrospective datasets of CS I patients with post-pubertal teratoma with somatic malignant component (TSMC) suggested these patients had inferior five-year OS of approximately 10% compared to other CS I GCT patients. Furthermore, CS I TSMC cases undergoing primary RPPLND had a much higher proportion of nodal metastases (PS II) than expected (37.5%). Despite its limitations, this study provides the only evidence on this issue and supports primary RPLND in CS I NSGCT with TSMC [146].

For patients presenting with CS I pure post-pubertal teratoma without a somatic malignant component, surveillance provides comparable survival outcomes to primary RPLND [147]. A mixed population based study on 237 CS I with pure teratoma in the testis, showed an increasing trend favouring surveillance over RPLND as well as a not significant difference in overall survival at a median follow-up of 54 months [147].

However, subtype discrepancies in primary diagnostic of post-pubertal teratoma are not infrequent and consist in addition of subtype and involve secondary somatic type of malignancy in 83% of cases. As such, central review by expert genitourinary pathologist is recommended when teratoma is diagnosed in the orchidectomy specimen [148].

6.1.3.6 Summary of evidence and recommendations for the treatment of clinical stage I non-seminoma germ cell tumour of the testis


Summary of evidence	LE
Lymphovascular invasion increases the risk of relapse.	2a
The relapse rate with active surveillance is up to 50%, when LVI is present.	2a
The relapse rate in patients who receive adjuvant chemotherapy with BEP (x 1 cycle) is up to 3%.	2a
Adjuvant chemotherapy with BEP x 1 is superior to adjuvant RPLND in terms of the risk of relapse when the 2 strategies are not centralised in expert centres.	1b
A risk-adapted approach, based on LVI invasion is feasible.	2b
The acute toxicity of one cycle adjuvant BEP is low.	1b

Recommendations	Strength rating
Inform patients about all management options after orchidectomy: surveillance, adjuvant chemotherapy, and retroperitoneal lymph node dissection, including treatment-specific recurrence rates as well as acute and long-term side effects.	Strong
Offer surveillance or risk-adapted treatment based on lymphovascular invasion (see below).	Strong
Discuss one course of cisplatin, etoposide, bleomycin as an adjuvant treatment alternative in patients with stage I non-seminomatous germ cell tumour if patients are not willing to undergo or comply with surveillance.	Strong

6.1.3.7 Recommendations for risk-adapted treatment for clinical stage I non-seminomatous germ cell tumour based on vascular invasion

Recommendations	Strength rating
Stage IA (pT1, no vascular invasion): low risk	
Offer surveillance if the patient is willing and able to comply.	Strong
Offer adjuvant chemotherapy with one course of cisplatin, etoposide, bleomycin (BEP) in low-risk patients not willing (or unsuitable) to undergo surveillance.	Strong
Stage IB (pT2-pT4): high risk	
Offer adjuvant chemotherapy with one course of BEP, or surveillance and discuss the advantages and disadvantages.	Strong
Offer surveillance to patients not willing to undergo adjuvant chemotherapy.	Strong
Offer nerve-sparing retroperitoneal lymph node dissection to highly selected patients only; those with contraindication to adjuvant chemotherapy and unwilling to accept surveillance.	Strong

Figure 1: Risk-adapted treatment in patients with clinical stage I non-seminoma NSGCT*



* Discuss all treatment options with individual patients, to allow them to make an informed decision as to their further care.

** In case of PS II, the rate of recurrence is higher and chemotherapy can be administered (max. 2 cycles).

BEP = cisplatin, etoposide, bleomycin; CS = clinical stage; IGCCCG = International Germ Cell Cancer Collaborative Group; NS = nerve-sparing; RLND = retroperitoneal lymph node dissection; VIP = etoposide, cisplatin, ifosfamide.

6.2 Metastatic germ cell tumours

The first-line treatment of metastatic GCTs depends on:

- I. the histology of the primary tumour;
- II. prognostic groups as defined by the IGCCCG (Table 4) [45];
- III. serum tumour marker decline at the end of the first cycle of chemotherapy in poor-prognosis patients.

In relapsed patients, a prognostic score has been developed including response to first-line therapy which can be used to estimate patient outcome following salvage chemotherapy [149].

6.2.1 Clinical stage I with (persistently) elevated serum tumour markers

With elevated markers and CS I, weekly measurement of markers are recommended. If AFP or β -hCG increase or fail to normalise following orchidectomy, US examination of the contralateral testicle must be performed. If a contralateral tumour is excluded, unequivocal rising tumour markers indicates CS I, and treatment for good prognosis metastatic GCT should be given. With stable markers, a new staging procedure, 4-6 weeks after orchidectomy, is recommended.

Some patients may have stable but slightly elevated AFP or β -hCG and can be initially monitored. Treatment should be commenced if markers rise or when follow-up imaging demonstrates metastatic disease.

The treatment of true CS I SGCT should be the same as other metastatic GCT. With this, ten-year overall survival of 95%, have been reported [150, 151].

6.2.2 Metastatic disease (stage IIA/B)

6.2.2.1 Stage IIA/B seminoma

Patients with enlarged retroperitoneal lymph nodes < 2 cm in greatest diameter and normal markers may be observed for six to eight weeks with repeat-staging imaging as these may be non-metastatic on average in 10% of cases. Treatment should only be initiated if metastatic disease is unequivocal, based on biopsy, increasing nodal size/number, or subsequent marker rise [46, 150]. A special case are those patients who can undergo primary RPLND within a trial or institutional study (see below for further details).

Historically, radiotherapy has been the primary treatment for stage II A/B seminoma, showing relapse rates between 9-24% [152, 153]. Recommended radiation doses for stage IIA and IIB are 30 Gy and 36 Gy, respectively. With these doses, five-year relapse-free survival rates stand at 92% for stage IIA and 90% for IIB [152, 153]. A reduced dose of 27 Gy for stage IIA has been associated with a higher relapse rate [105].

Chemotherapy is a standard option for stage IIA/B seminoma, with relapse rates of 0-8% for stage IIA disease and 8-14% for stage IIB disease, and an excellent overall survival of 99% [154, 155]. The standard regimen in stage II seminoma is BEP x 3 (see Appendix 4.1.2) or EPx4 if there are concerns with the use of bleomycin [156]. There are no randomised studies comparing radiotherapy and chemotherapy. A meta-analysis of thirteen high-quality studies, comparing efficacy and toxicity of radiotherapy and chemotherapy showed that these appeared similarly effective in both stage IIA/IIB patients although with a non-significant trend towards greater efficacy for chemotherapy (HR: 2.17) in stage IIB seminoma [154]. Acute toxicity was almost exclusively reported following chemotherapy, while long-term toxicity was more frequent following radiotherapy, mainly comprising bowel toxicity and secondary cancers, generally in the irradiated field [154]. Several series have shown an increased risk of developing a second solid cancer of 1.8-2.0-fold with radiotherapy [157]. Long term toxicities of chemotherapy including second cancers are also a concern [157].

6.2.2.1.1 Retroperitoneal lymph node dissection

Several institutional series and a few single-arm phase II studies have explored primary RPLND with or without adjuvant chemotherapy as an alternative to chemotherapy in men with low volume CS II A/B [158-162]. Differences in surgical technique/template, extent of use of adjuvant chemotherapy, patient selection, and length of follow-up make direct comparisons of these surgical series to chemotherapy difficult. In these reports, patients with low-volume CS II A/B seminoma had two-year recurrence rates of 5-30%, with immature OS outcomes owing to short follow-up. Relapse will almost always be cured by standard chemotherapy. Longer

follow-up and ideally, comparative prospective studies are required to ensure this can be recommended as a safe stand-alone treatment option equivalent to chemotherapy alone.

Primary RPLND for men with low volume CS II seminoma should only be performed by surgeons with extensive experience in specialised TC centres. Ideally, the procedure should take place within a prospective cohort or clinical trial in order to maintain surgical quality and monitor long-term oncological outcomes.

6.2.2.1.2 De-escalating approaches


Several trials attempted to de-escalate chemotherapy and RT, aiming at maintaining the traditional excellent oncologic result, while minimising treatment burden and toxicity.

Such an approach was evaluated in a phase II randomised trial, assessing chemotherapy de-escalation in patients guided by metabolic response on FDG-PET/CT after two initial cycles of etoposide, cisplatin (EP) chemotherapy [163]. Patients with complete metabolic response after EP x 2 received de-escalated treatment with one subsequent cycle of carboplatin AUC7, whilst patients with residual metabolic activity completed the initial schedule of EP x 4. The study showed comparable three-year PFS rate of 90% and 91% for the EP and carboplatin groups respectively, and a two-year OS of 100% for both groups. Despite the apparently maintained oncological efficacy, larger studies and longer follow-up is needed. For these reasons and owing to the absence of consensus criteria for FDG-PET/CT interpretation, making treatment decisions based solely on FDG-PET/CT responses is not currently recommended for routine use [163].

Another de-escalation option emerged, involving one cycle of carboplatin followed by involved-node (small-volume) radiotherapy (30 Gy in 15 sessions for stage IIA and 36 Gy in 18 sessions for stage IIB). This approach has shown a three-year progression-free survival rate of 93.7% in a single-arm phase II trial, narrowly missing its target primary endpoint of 95% three-year PFS [164]. Currently such approaches lack the level of evidence needed for routine use recommendation.

Summary of evidence	LE
At this stage all de-escalation strategies, including RPLND remain under evaluation and should only be considered in high volume specialised centres within a prospective cohort or clinical trial.	3

Figure 2: Treatment options in patients with seminoma clinical stage IIA and B*



**when enlarged retroperitoneal lymph nodes are < 2 cm and with normal markers, treatment should not be initiated unless metastatic disease is unequivocal based on biopsy, increasing nodal size/number, or subsequent marker rise.*

BEP = cisplatin, etoposide, bleomycin; EP = etoposide, cisplatin.

6.2.2.2 Stage II A/B non-seminoma (NSGCT)

6.2.2.2.1 Serum tumour marker negative

Patients with normal markers and equivocal lymph nodes (< 2 cm) may be considered for initial surveillance with early re-evaluation at six weeks. If the lesion progresses or fails to resolve it should be regarded and treated as CS II.


With CS IIA NSGCT disease and normal or normalised tumour markers, nerve sparing RPLND performed by an experienced surgeon in a specialised centre is the recommended initial treatment. Patients may be down staged to PS I in up to 20% of cases and require no further treatment. Patients with post-pubertal teratoma alone will avoid unnecessary chemotherapy as surgery alone is curative. The oncological outcomes after RPLND in CS II NSGCT have been evaluated in a SR [165]. Of the included studies the majority were retrospective with included patients differing substantially in histopathology, size and number of retroperitoneal lymph nodes resected, surgical templates, and the use of adjuvant chemotherapy. In men with marker negative CS II NSGCT, PS II is confirmed in 80%. Without adjuvant chemotherapy 12-40% recurred compared to 0-4% in those who received adjuvant chemotherapy.

These findings align with large single centre reports of outcomes following RPLND alone for PS II NSGCT with active disease [116, 123, 124, 166]. These studies reported five-year relapse of less than 30%, with the majority occurring outside the retroperitoneum requiring systemic chemotherapy according to risk group.

Adjuvant chemotherapy may be discussed with the patient to reduce the risk of relapse in this setting. Key issues include risk factors for relapse (as positive lymph node-ratio), the risk of overtreatment in up to 70% of cases and the need for rigorous follow-up. When adjuvant chemotherapy is chosen, standard treatment is BEP or EP for a maximum of two cycles [165, 167].

A recent single institution real world study including 61 CS IIA/B < 3cm NSGCT (out of 66 GCT) with active disease, showed a 77% two-year progression-free survival without adjuvant chemotherapy in stage IIA/B < 3 cm, with the greatest benefit was achieved in stage IIA marker negative cases [166].

Figure 3: Flowchart Nonseminoma CS IIA Mk- at Diagnosis/Staging



* Most of the patients will be good prognostic group (BEP x3 or PE x4).

TM – tumour markers

* With marker negative PD > IIB RPLND may be considered if radiological features of teratoma

** Most will be good prognostic group (BEP x3 or EP x4) - see Appendix 4

[https://uroweb.org/guidelines/testicular-cancer/publications-appendices.](https://uroweb.org/guidelines/testicular-cancer/publications-appendices)

***In case of PS II A/B patient can be followed-up or receive adjuvant chemotherapy (maximum of 2 cycles).

6.2.2.2 Serum tumour marker positive

Patients with elevated tumor markers and radiological stage IIA/B at diagnosis or relapse should be treated with chemotherapy as outlined in tables 6 and 7 and section 6.2.3.1 based on IGCCCG risk group. Most patients will have a good prognosis for whom BEPX3 is most appropriate or EP x 4 if there are concerns with the use of bleomycin.

Primary RPLND for CS IIA/B disease with elevated markers is not recommended outside a specific study in a referral centre [166, 168].

6.2.3 **Metastatic disease (stage II C and III)**

6.2.3.1 *Primary chemotherapy*

6.2.3.1.1 Good-prognosis risk group - seminomatous germ cell tumour

For metastatic seminoma, a cisplatin-based regimen should be used. A cisplatin-based combination chemotherapy has shown superior efficacy over carboplatin-based regimens [169]. The standard regimen in good-risk seminoma is three, twenty-one days cycles of BEP (Table 6). Alternatively, EP x 4 may be considered especially when bleomycin is contraindicated [170]. This achieves similar response rates but may have a slightly higher risk of relapse.

Post-chemotherapy masses should be managed as described in Section 6.5.2.

6.2.3.1.2 Intermediate-prognosis risk group - seminomatous germ cell tumour

For patients with intermediate-risk seminoma, BEP x 4 is the standard regimen. In bleomycin is contraindicated the combination of etoposide, cisplatin, ifosfamide (VIP) should be given. No RCT has focused specifically on this rare group of patients (see Table 4).

6.2.3.1.3 Good-prognosis risk group - non-seminomatous germ cell tumour

The standard regimen in good-risk non-seminoma is BEP x 3 (Table 6) [170].

An RCT support the equivalence of three or five-day regimes with three or four cycles of BEP for projected two-years PFS. Three-day regimes are associated with increased toxicity [171, 172]. Based on these data the BEP x 3 as a five-day regimen is strongly recommended in the good-prognosis risk group.

Two RCTs support the superiority of BEP x 3 over other regimes or schedule intensities [156, 173]. A further RCT has suggested that when EP is used, the mortality rate is twice that of with BEP, although the difference did not reach statistical significance [156].

Patients with a clear contraindication to bleomycin may receive EP x 4 [171]. In all other cases omission of bleomycin is not recommended.

For more information regarding Chemotherapy protocols, please visit the EAU guidelines website:

<https://uroweb.org/guidelines/testicular-cancer/publications-appendices>

6.2.3.1.4 Intermediate-prognosis risk group - non-seminomatous germ cell tumour

The standard regimen is BEP x 4 [174]. Four cycles of VIP has similar efficacy but is more myelotoxic [175]. Four cycles of VIP including primary G-CSF prophylaxis should be applied in patients with contraindications to bleomycin.

6.2.3.1.5 Poor-prognosis risk group - non-seminomatous germ cell tumour

The standard regimen is four cycles of BEP. Four cycles of VIP have similar efficacy, but is more myelotoxic [175]. Four cycles of VIP including primary granulocyte colony stimulating factor (G-CSF) prophylaxis should be applied in patients with contraindications to bleomycin [176, 177].

Serum tumour marker decline is the only prospectively confirmed predictor for response to cisplatin chemotherapy in metastatic germ cell tumour patients. Patients with inadequate tumour marker decline after the first or second cycle of BEP represent a prognostically inferior subgroup [177, 178]. There are several ways to calculate tumour marker decline kinetics with an example available at:

<https://www.gustaveroussy.fr/calculations-tumeur/NSGCT.html>.

An RCT demonstrated improved PFS when intensifying treatment with dose-dense chemotherapy in patients with an early unfavourable tumour marker decline [179]. The trial was not powered to estimate OS differences. Based on the results from this trial, patients with an unfavourable tumour marker decline after BEP x 1 can be switched to a more intensive (dose-dense) chemotherapy regimen [179]. Additional patient groups with an unfavourable prognosis on standard treatment are primary mediastinal non-seminoma and patients with brain metastases at initial diagnosis [100, 180]. These may also be candidates for upfront intensified treatment, preferably in a prospective study.

In RCTs, primary high-dose chemotherapy (HDCT) with subsequent autologous stem cell transplantation has not shown an OS benefit in the overall poor-prognosis patient population in RCTs [176, 177]. Selected patients, such as primary mediastinal nonseminoma, do have poor survival following standard dose chemotherapy [181]. They may derive a benefit from primary HDCT [182], preferably within a prospective protocol.

Better outcomes are reported for intermediate and poor prognosis patients treated at high-volume centres [183-185]. Due to their unfavourable survival, poor-prognosis patients should be managed at centres with interdisciplinary germ cell tumour expertise and treated in ongoing prospective trials or registries, whenever possible.

There are no general recommendations for treatment modifications for patients with poor performance status (Karnofsky < 50%) or extended liver infiltration (> 50%), although two small patient series indicate that an initial cycle of dose-reduced therapy may reduce acute mortality without compromising long-term outcomes. The number of subsequent cycles of full-dose therapy should, however, not be reduced after an initial low-dose induction cycle [184, 186].

Patients with widespread pulmonary metastases are at risk for pulmonary haemorrhage and subsequent acute respiratory distress syndrome (ARDS) with induction chemotherapy. To reduce this risk, primary cytoreductive induction chemotherapy with EP over two to three days should be administered, followed by the first cycle of standard chemotherapy when the risk of ARDS has passed (typically after ten days) [184].

Table 6: Level of evidence for prognostic group and treatment

Prognostic group IGCCCG	Treatment	LE
Good (SGCT and NSGCT)	BEP x 3 or EP x 4	1b
Intermediate (SGCT and NSGCT)	BEP x 4 or VIP x 4	1b
Poor (NSGCT)	BEP x 4 or VIP x 4 if favourable marker decline	1b
	Dose escalation in selected cases with inadequate serum tumour marker decline	1b

6.2.3.1.6 Prevention of thromboembolism events during chemotherapy

Some RCTs have assessed the risks and benefits of thromboprophylaxis in ambulatory cancer patients receiving chemotherapy and report a relative risk reduction of 30-60% in venous thromboembolic events (VTE) at the cost of a doubling in bleeding risk [187-190]. Based on these results, the most recent American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Update recommends thromboprophylaxis with apixaban, rivaroxaban, or low molecular weight heparin (LMWH) to cancer patients with a high risk of VTE and low risk of bleeding [191]. Metastatic germ cell tumour (mGCT) patients were under-represented in all trials and thus, it is not clear whether this recommendation applies to this group although retrospective data suggests a similar efficacy of VTE prophylaxis [192].

The EAU Guideline panel has discussed a recommendation regarding thromboprophylaxis. All members agreed that men with mGCTs undergoing cisplatin-based chemotherapy are at high-risk for VTE, and with the exception of those with choriocarcinoma and high volume extra-peritoneal disease, are at low risk of bleeding. Given the apparent high VTE incidence* and only non-validated VTE risk factors, the panel preferences were divided between those panel members that favoured thromboprophylaxis in all men and those panel members that restricted thromboprophylaxis to men with certain risk factors. Additionally, the majority of the panel agreed that a central venous-access device should be avoided whenever possible as this represents the only modifiable risk factor, which remained significantly associated with VTE in a multivariable risk-prediction model [193, 194].

*For more information regarding the prevention of thromboembolism events during chemotherapy, please see appendix 2, available online <https://uroweb.org/guidelines/testicular-cancer/publications-appendices>.

6.2.3.1.7 Summary of evidence and recommendations for the prevention of thromboembolism events during chemotherapy

Summary of evidence	LE
Thromboembolic events occur more frequently in male patients with GCTs receiving chemotherapy than in young males under chemotherapy for other cancers.	2b
Retrospective studies have identified multiple risk factors for the development of thromboembolic events including increasing stage, size of retroperitoneal lymph nodes at different cut-offs, Khorana score > 3 and indwelling vascular access device (only modifiable risk factor).	2b

Recommendations	Strength rating
Balance the individual patients' potential benefits and risks of thromboprophylaxis during first-line chemotherapy in men with metastatic germ cell tumours.	Weak
Avoid use of central venous-access devices during first-line chemotherapy whenever possible.	Weak

6.3 Treatment evaluation and further treatment

6.3.1 Treatment evaluation

Response to treatment should be assessed after the initial induction cycle by repeat imaging and/or re-evaluation of tumour markers. With marker decline and/or radiologically regressing or stable tumour features, the planned chemotherapy should be completed [192, 194]. If markers decline, but metastases progress on imaging, induction therapy must be completed [195]. If markers have normalised and masses with features of post-pubertal teratoma progress early surgical resection should be considered.

Slow marker-decline with the initial one to two cycles of chemotherapy warrants consideration for dose intensification (see <https://www.gustaveroussy.fr/calculations-tumeur/NSGCT.html>).

Following completion of treatment, cases with a low-level β -hCG plateau should be observed to determine whether complete normalisation subsequently occurs. In patients with a low plateau serum AFP level after chemotherapy, removal of residual masses should be undertaken, with subsequent AFP monitoring. Preoperative AFP levels of > 30 μ g/l and viable cancer found in the histological examination of the resected specimen have been described as predictors of relapse after first line chemotherapy [196]. Salvage chemotherapy is thus only indicated for documented marker progression [195, 197].

6.3.2 Residual tumour resection

6.3.2.1 Seminoma

A residual mass of seminoma should initially be monitored with imaging and tumour markers [198-200].

As FDG-PET has a high NPV, in patients with residual masses > 3 cm in largest diameter, this should be considered in order to provide more information on disease viability [201-203]. It should not be performed until at least two months after completion of chemotherapy, as inflammation and the desmoplastic reaction induced by chemotherapy may result in a false positive result [204]. The NPV for active disease is > 90% which can be reassuring [201, 202]. In contrast PPV ranges from 23-69% and thus caution is advised on initiating active therapy driven only by positive findings on FDG-PET-CT [205].

When a post-chemotherapy mass remains positive at reclassification with FDG-PET with no volume increase, repeat FDG-PET should be performed six weeks later. A recent publication shows a low PPV for vital tumours in residual lesions (generally > 3 cm) after chemotherapy in metastatic seminoma (11-38% depending on subgroup). Therefore, caution is recommended with FDG-PET as a single parameter to drive clinical decisions in a persistent mass [205]. In patients with progressive disease on radiological criteria (i.e., a growing mass which enhances with CECT or is FDG-PET avid), salvage therapy is indicated [206-208].

Patients with persistently high and/or progressing β -hCG elevation after first-line chemotherapy should proceed to salvage chemotherapy. Progressing patients without β -hCG progression should undergo histological verification (e.g., by percutaneous or surgical biopsy) before salvage chemotherapy is given. When RPLND is indicated, this should be performed in referral centres, as residual seminoma masses may be extremely difficult to remove due to intense fibrosis [207].

6.3.2.2 *Non-seminoma*

Following first-line BEP it has been reported that about 7% of residual masses contain active cancer, 33% post-pubertal teratoma, and 40% necrotic-fibrotic tissue only [209]. The remainder comprise rarer entities including malignant transformation of teratoma. Restaging patients following chemotherapy with FDG-PET is not indicated [54, 55, 204]. With complete radiological remission, RPLND is not indicated [210, 211].

Usual timing for restaging is three to four weeks after the beginning of the last cycle. No diagnostic or risk calculator can accurately predict histology of the residual masses. Thus, resection is mandatory in all patients with a residual mass > 1 cm in transaxial long axis at cross-sectional CECT imaging until novel predictive models are externally validated [212-215]. Surgery when indicated should be performed within six to eight weeks after the last chemotherapy cycle.

The role of surgery with residual retroperitoneal lesions < 1 cm is uncertain. It is difficult to distinguish between a true residual node below 10 mm and a complete remission, and many authors consider these situations as equivalent. Residuals containing cancer or teratoma are possible, but the vast majority of patients have fibro-necrotic tissue only [216]. Whilst post-chemotherapy RPLND with residuals < 10 mm in transaxial long axis or complete remission is an option [217], the alternative option is close surveillance with recurrence risk of 6-9% depending on the follow-up duration [209-211, 218]. In the series with the longest follow-up of 15.5 years, twelve (9%) of 141 patients relapsed despite a complete response following primary treatment [211, 218]. Eight of the twelve relapsing patients were cured with subsequent treatment. These cases should be discussed on individual basis considering the orientation and expectations of the patient.

Residual masses after salvage chemotherapy or HDCT in first or subsequent salvage situations have a greater risk of active disease [219]. Surgery is therefore indicated even with residual masses < 1 cm [210, 211].

When resection is indicated, bilateral nerve sparing RPLND is the standard option. Ipsilateral template resection avoids contralateral nerve dissection and may be considered for residuals with a diameter < 5 cm [220], as well as unilateral lymph node metastases on pre- and post-chemotherapy CT scans, left-sided tumours only require para-aortic resection whereas right-side tumours need paracaval and inter-aortocaval resection down to the iliac arteries [221, 222]. Mapping studies indicate the potential risk of contralateral disease with this approach is low at around 1-3% [221, 223]. The mere resection of the residual tumour (so called lumpectomy) should not be performed [211, 215, 216, 219, 220, 222, 224].

Laparoscopic or robotic RPLND may yield comparable outcomes to open procedures in selected cases, with low-volume residual disease and when undertaken by highly experienced surgeons. This should only be considered in specialist TC centres with expertise in open RPLND and minimally invasive surgery to ensure appropriate case selection. In this setting, up to 30% of post-chemotherapy RPLND have been reported via a laparoscopic approach [225-227]. Experience with robot-assisted laparoscopic RPLND, and specifically long-term outcomes remains limited [228]. Atypical recurrences have been reported and occur more often with this approach [128].

6.3.3 **Sequencing of surgery in the case of multiple sites**

In general, surgery should commence at the site with the highest volume of residual disease. The histology of the mass diverges in different organ sites [212]. In cases of residual retroperitoneal and lung masses, the presence of fibro-necrotic tissue in the retroperitoneum is associated with a probability as high as 90%, that lung masses contain the same histology [229]. When pathologic examination of the lesions from the initial side show complete necrosis, observation may be considered when there are multiple contralateral tumours for which resection may be challenging. Discordant histology between lung sites, however, may occur in up to 20% of cases and thus, patients in this situation should be closely monitored with reconsideration of surgery or biopsy if radiological features change [230, 231].

6.3.3.1 Quality and intensity of surgery

Resection of visceral structures and/or major vessels, requiring vascular reconstruction/replacement may be required to achieve radical resection and patients undergoing adjunctive complex surgery have a greater risk of complications [232, 233]. In patients with intermediate- or poor-risk and residual disease > 5 cm, the probability of vascular procedures is as high as 20% [234]. These cases must therefore be referred to specialised centres capable of interdisciplinary surgery (gastro-enteric and vascular surgery, spinal neurosurgery, thoracic surgery). Even with centralisation of treatment, the median number of RPLNDs performed per surgeon/year in the U.K. is six [235]. Nevertheless, patients treated within such centres benefit from a significant reduction in peri-operative mortality from 6% to 0.8% [236]. In addition, specialised urologic surgeons are capable of reducing the local recurrence rate from 16% to 3% with a higher rate of complete resections [237].

6.3.3.2 Salvage and desperation surgery

Surgery of resectable disease after salvage treatment remains a potentially curative option in patients with any residual mass following salvage chemotherapy. Survival after surgery and first salvage chemotherapy improved by 70% at ten years, following taxane-containing regimens [238]. Even with extensive salvage chemotherapy, surgery remains a fundamental tool to achieve durable complete remissions in up to 20% of patients [239, 240].

Desperation surgery refers to resection of non-responsive or progressive (e.g., rising markers) disease following salvage chemotherapy. When the disease is resectable, a significant proportion of these patients can be rendered disease-free in the long term [241].

6.3.3.3 Consolidation chemotherapy after secondary surgery

After resection of necrosis or post-pubertal teratoma, no further treatment is required. With incomplete resection of viable cancer, two adjuvant cycles of conventionally dosed cisplatin-based chemotherapy may be given in certain subgroups (e.g., poor-prognosis patients) [224]. Caution is required with cumulative doses of bleomycin which should not exceed 12 in total. With complete resection of active disease, comprising < 10% of the total volume of the mass, particularly in patients who initially had a good-prognosis based on IGCCCG criteria, the relapse rate is very low and adjuvant chemotherapy is not beneficial in preventing further relapse [242]. The prognosis is worse if malignant disease is present in masses resected after second- and third-line chemotherapy, although further chemotherapy is not indicated [243].

6.3.4 Systemic salvage treatment for relapse or refractory disease

Cisplatin combination salvage chemotherapy will result in long-term remissions in approximately 50% of patients who relapse after first-line chemotherapy. These results are highly dependent on several prognostic factors [244]. The regimens of choice are four cycles of a three-agent regimen including cisplatin and ifosfamide plus a third drug: etoposide (VIP), paclitaxel (TIP), or potentially gemcitabine (GIP) (Table 7) [245, 246]. No RCT has compared these regimens. Due to their potential risk of lethal haematological toxicity, these regimens should be used with G-CSF support and by well-trained oncologists.

Table 7: Standard VIP, TIP and GIP salvage chemotherapy (interval 21 days)

Regimen	Chemotherapy agents	Dosage	Duration of cycles
VIP	Cisplatin*	20 mg/m ²	Days 1-5
	Etoposide	75-100 mg/m ²	Days 1-5
	Ifosfamide*	1.2 g/m ²	Days 1-5
TIP	Paclitaxel	250 mg/m ² ^{xx}	24 hour continuous infusion day 1
	Ifosfamide*	1.5 g/ m ²	Days 2-5
	Cisplatin*	25 mg/m ²	Days 2-5
	Alternative schedule		
	Paclitaxel	175 mg/m ²	Day 1, 3 hour infusion
	Ifosfamide*	1.2 g/m ²	Days 1-5
	Cisplatin*	20 mg/m ²	Days 1-5
GIP	Gemcitabine	1000 mg/m ²	Day 1 + 5
	Ifosfamide	1200 mg/m ²	Days 1-5
	Cisplatin	20 mg/m ²	Days 1-5

^{xx} An MRC schedule uses paclitaxel at 175 mg/m² in a 3 hour infusion [246].

Please refer to appendix 4 – Chemotherapeutic protocols <https://uroweb.org/guidelines/testicular-cancer/publications-appendices> for more detailed information.

A retrospective analysis by the International Prognostic Factors Study Group (IPFSG) evaluated the risk of relapse in patients in whom this occurred after at least three cisplatin cycles and subsequent cisplatin conventional-dose or carboplatin-based high-dose salvage chemotherapy [149]. Seven variables: histology, primary tumour location, response, progression-free interval after first-line treatment and level of AFP, β -hCG and the presence of liver, bone or brain metastasis at salvage treatment, were identified as independent prognostic variables of relapse after initial cisplatin chemotherapy [149]. Using these factors, five risk-groups: very low-risk = -1 points; low-risk = 0 points; intermediate-risk = 1-2 points; high-risk = 3-4 points; and very high-risk > 5 points; were identified with significant differences in PFS and OS. Table 9 illustrates these five risk groups and the corresponding two-year PFS and three-year OS rates [149]. Several recent trials have validated this scoring system [247-250]. As in first-line therapy, the prognostic impact of tumour marker decline applies in the salvage setting [251]. While progression to induction chemotherapy was negative for OS, prior use of paclitaxel was not significantly associated with a negative outcome [252].

A secondary analysis of the IPFSG cohort (n = 1,600 patients) showed a 10-15% improvement in OS in all prognostic subgroups when treated with high-dose salvage therapy compared to standard dose therapy. This is being evaluated in an RCT of HDCT vs. conventional dose chemotherapy in patients with first-line relapse is underway (Tiger trial). When HDCT is used as a salvage treatment, sequential treatment cycles of high-dose carboplatin and etoposide (HD-CE) should be preferred to a single high-dose regimen as the former is associated with less toxicity-related deaths [247]. A recent SR confirmed the superiority of using at least two high-dose cycles in the salvage setting over a single high-dose cycle [253]. It is clearly of the utmost importance that these rare patients with relapse are treated within clinical trials and at specialised centres.

Table 8: The International Prognostic Factors Study Group Score for seminoma and non-seminoma that relapse after cisplatin-based first-line chemotherapy [189]

Points	-1	0	1	2	3
Variable					
Histology	Seminoma	Non-seminoma			
Primary site		Gonadal	Retroperitoneal		Mediastinal
Response		CR/PRm-	PRm+/SD	PD	
PFI		> 3 months	≤ 3 months		
AFP salvage		Normal	< 1000	1000	
hCG salvage		< 1000	1000		
LBB		No	Yes		

AFP = alpha-fetoprotein; CR = complete remission; PRm- = partial remission, negative markers; PRm+ = partial remission, positive markers; hCG = human chorionic gonadotrophin; LBB = liver, bone, brain metastases; PD = progressive disease; PFI = progression-free interval; SD = stable disease.

Table 9: PFS and OS estimates for all patients according to IGCCCG prognostic score for seminoma and non-seminoma that relapse after cisplatin-based first-line chemotherapy [190]

Score (n = 1,435)	N	%	HR	2-years PFS (%)	3-year OS (%)
Very Low	76	5.30	1	75.1	77.0
Low	257	17.9	2.07	52.6	69.0
Intermediate	646	45.0	2.88	42.8	57.3
High	351	24.5	4.81	26.4	31.7
Very High	105	7.3	8.95	11.5	14.7
Missing	159	-	-	-	-

HR = hazard ratio; PFS = progression-free survival; n = number of patients; OS = overall survival.

6.3.5 **Second relapse**

No RCTs have been reported for patients with second relapse and conventional therapy appears to have limited effect. For patients who have received two series of conventionally dosed therapy (first line and first-salvage), HDCT with autologous stem cell support should be used although the prospect of cure is < 25% [248]. Retrospective data from Indiana University suggest that patients who completed HDCT may derive additional benefit from daily maintenance therapy with oral etoposide for three months post HDCT [254]. Prospective evaluation of this in a randomised phase II trial is ongoing.

Patients relapsing within four to eight weeks after platinum-based therapy, or who are progressing despite platinum-based therapy, as well as those relapsing shortly after HDCT, are considered as cisplatin refractory. Combinations of gemcitabine and oxaliplatin or the triple combination of gemcitabine, oxaliplatin and paclitaxel have resulted in response rates of 25-45% in this setting. Cisplatin re-challenge in association with gemcitabine and paclitaxel may be considered in patients with adequate renal function [255]. For patients with a second relapse not responding to the combination of oxaliplatin and gemcitabine or the triple combination, inclusion in clinical trials is encouraged.

Patients with a good response undergoing subsequent resection of residual tumour lesions may still have a 15-20% chance of long-term cure [239, 256].

Various targeted agents have generally failed in refractory disease, including immune checkpoint inhibitors [247-253, 257]. Trials combining PD1/PDL-1 and CTLA4 inhibitors are ongoing, however, even for those combinations early results are not encouraging.

6.3.5.1 *Late relapse (more than two years after end of first-line treatment)*

Late relapse is defined as recurrence more than two years after completion of successful primary treatment of metastatic TC [203, 258]. According to a pooled analysis, this occurs in 1.4% and 3.2% of seminoma and non-seminoma patients, respectively [259].

Based on a population-based study, all late-relapsing seminoma patients have viable GCT [260]. These can be treated with chemotherapy and radiotherapy [261].

In contrast, patients with late-relapsing NSGCT should undergo surgical resection when feasible, alone or in combination with chemotherapy. Some patients, including those with rapidly rising β -hCG, may benefit from induction salvage chemotherapy with subsequent reconsideration of surgery for resection of persisting residual masses [262]. In general, however, surgery represents the mainstay of treatment and it should be performed in most patients when feasible irrespective of the level of their tumour markers, in order to completely resect all viable GCT post-pubertal teratoma [261-265].

Survival strongly relates to the histology of the recurrent lesions rather than that of the initial disease. If not completely resectable, biopsies should be obtained for histological evaluation to direct salvage chemotherapy based on the tumour phenotype. Review by an experienced pathologist is critical to avoid misinterpretation of the therapeutic morphological changes that occur with the treatment of GCT [266]. If the patient responds to salvage chemotherapy, secondary surgery should then be undertaken if feasible. With unresectable, but localised refractory disease, stereotactic or conventional radiotherapy may be considered. To avoid excess mortality, late relapses should be treated only at centres experienced in managing such patients [267].

6.3.6 **Treatment of brain metastases**

Brain metastases occur in the context of initial metastatic disease, systemic relapse and rarely as an isolated site of relapse. Long-term survival of patients presenting with brain metastases at diagnosis is poor (30-50%) and even poorer when a site of recurrent disease (five-year survival-rate is 2-5%) [268, 269]. A large international database comprising 523 patients reported 48% three-year OS rates in patients with brain metastases at initial diagnosis and 27% three-year OS rates for patients with brain metastases at relapse [58].

Chemotherapy as initial treatment proved effective in a first-line setting (potentially even as dose-intensified therapy upfront) with data also supporting the use of multimodal treatment particularly in relapsed disease [58]. Consolidation RT, even with total response after chemotherapy, should therefore be used in patients with brain metastases at relapse, but must be carefully discussed in a first-line setting [270]. Surgery may be considered in cases with a persistent solitary metastasis, depending on the systemic disease status, histology of the primary tumour and the location of the metastasis.

6.3.6.1 Summary of evidence and recommendations for the treatment of metastatic testicular germ cell tumours

Summary of evidence	LE
In the NSGCT good-prognosis-risk group (IGCCG), BEP x 3 is superior to other chemotherapy regimens. Toxicity is lower when treatment is delivered in five-day regimes rather than three-day regimes.	1b
In the NSGCT intermediate-prognosis-risk group (IGCCG) BEP x 4 is the standard treatment of choice with a five-year survival of 89% in contemporary series.	1b
In pathological stage II NSGCT disease, RPLND performed in specialised centres without adjuvant chemotherapy results in 73-81% of long-lasting remissions.	2b
In patients with a poor-prognosis metastatic NSGCT (defined by IGCCG), treatment with BEP x 4, results in a five-year PFS of 67%. There is no advantage in OS for high-dose chemotherapy.	1b
Patients with a poor-prognosis metastatic NSGCT and early unfavourable tumour marker decline may benefit from intensification of treatment with dose-dense chemotherapy, with improvement of PFS despite no benefit being observed for OS.	1b
Following first-line BEP chemotherapy, 6-10% of NSGCT residual masses contain active cancer, 50% have post-pubertal teratoma, and 40% comprise of necrotic-fibrotic tissue only. Figures regarding persistence of residual active are slightly lower in post chemotherapy residual masses < 1 cm. Currently there is no accurate prognostication method of histology.	2b
In CS IIA/B seminoma radiotherapy and chemotherapy treatment show similar effectiveness, with a non-significant trend towards greater efficacy of chemotherapy in CS IIB. However, risk of second malignancies and cardiovascular events is higher after radiotherapy.	2a
In metastatic seminoma stage > IIC, primary chemotherapy with BEP, tailored to the IGCCG risk group, has proven superior to Carboplatin based chemotherapy.	1b
Fluorodeoxyglucose-positron emission tomography has a high NPV in patients with post-chemotherapy seminoma residual masses (> 3 cm) when performed more than two months after chemotherapy.	2b

Recommendations	Strength rating
Treat low-volume non-seminomatous germ cell tumour (NSGCT) stage IIA/B with elevated markers like metastatic good- or intermediate-prognosis risk group IGCCG with three or four cycles of cisplatin, etoposide, bleomycin (BEP).	Strong
Nerve-sparing retroperitoneal lymph node dissection when performed by an experienced surgeon in a specialised centre is the recommended initial treatment in clinical stage (CS) IIA NSGCT disease without elevated tumour markers.	Weak
Repeat staging after six weeks before making a final decision on further management should be considered in patients with small volume (CS IIA < 2 cm) marker-negative NSGCT.	Weak
Treat metastatic NSGCT (stage > IIC) with an intermediate prognosis with four cycles of standard BEP.	Strong
Treat metastatic NSGCT with a poor prognosis and favourable marker decline with four cycles of BEP.	Strong
Assess tumour marker decline after one cycle of standard chemotherapy in metastatic NSGCT with a poor-prognosis. With unfavourable decline, consider chemotherapy intensification.	Weak
Perform surgical resection of visible (> 1 cm in longest diameter) residual masses after chemotherapy for NSGCT when serum levels of tumour markers are normal or normalising.	Strong
Offer cisplatin chemotherapy according to IGCCG prognosis groups, or alternatively radiotherapy to seminoma patients with stage II A/B and, inform the patient of potential long-term side effects of both treatment options.	Weak
Treat seminoma stage IIC and higher, with primary chemotherapy according to IGCCG classification (BEP x 3 in good-prognosis and BEP x 4 in intermediate prognosis).	Strong

7. FOLLOW-UP AFTER CURATIVE THERAPY

7.1 Minimal recommendations for follow-up

Based on different risks of relapse depending on diagnosis and initial treatment, three major follow-up groups can be defined:

1. patients with seminoma stage I;
2. patients with non-seminoma stage I on active surveillance;
3. all patients having received either adjuvant treatment or curative chemotherapy for good- and intermediate-prognosis metastatic disease (according to the IGCCCG) achieving a complete remission with, or without, surgery (for seminoma this includes residual lesions < 3 cm, or residual lesions > 3 cm that are FDG-PET-negative).

It is important to note that patients not achieving a complete remission or presenting with poor-prognosis disease should be followed up individually by specialised centres. Tables 10-12 show the minimal recommendations for follow-up of the three different groups based on recommendations developed at a European Society for Medical Oncology (ESMO) consensus conference [271].

Both MRI and CT can be used to evaluate the retroperitoneum, pelvis and inguinal regions for sites of metastatic disease from GCT [272, 273]. Magnetic resonance imaging benefits from an absence of ionising radiation but is more time consuming and less readily available than CT [274]. Given the frequency of follow-up, over a number of years some studies have estimated a risk of up to 1 in 300 of second malignancy related to CT imaging follow-up alone [275], although more recent dose saving protocols and limitations on field of view will have mitigated this somewhat. Nevertheless, this risk could be excluded by the use of MRI for follow-up.

Both MRI and CT rely predominantly on size cut-offs for evaluation given the excellent spatial resolution of both modalities, with morphological assessment for features such as necrosis and irregular shape an adjunct. Sensitivity and specificity vary according to the size cut-off used [272]. However, studies have shown comparable excellent results between MRI and CT with up to 98% sensitivity on MRI for the detection of retroperitoneal nodal metastases in GCT [276]. It has, however, been demonstrated that reader experience is important when interpreting images [277]. In the setting of GCT, one study demonstrated decreased sensitivity for detection of retroperitoneal nodal disease on MRI when reported by a trainee radiologist with sensitivity of detection of 80% [275]. However, experienced radiologists in the same study again achieved sensitivity for detection of nodal disease of 97% with good interobserver agreement. It was therefore suggested that if MRI is to be used instead of CT for follow-up this be done in centres/units with oncological radiologists who routinely report MRI and CT in patients with GCT rather than general radiologists who may only occasionally see such imaging. Consequently, MRI of the abdomen can be used as an alternative to CECT in experienced centres [278].

The diagnostic accuracy of FDG-PET-CT is best described and therefore recommended in seminoma patients with post-chemotherapy residual masses > 3 cm in largest diameter as outlined in section 6.3.2.1. This should be performed at least 2 months after completion of chemotherapy as earlier scans may be misleading due to inflammation. The changes related to tumour necrosis. The use of FDG-PET-CT is not currently recommended during surveillance. Retrospective analyses have indicated a high diagnostic accuracy for staging and follow-up in patients with CS 1 during surveillance or for determining the stage in more advanced disease [279]. However, to minimise radiation exposure and considering the supporting data for the use of MRI [273], the panel currently do not recommend the use of FDG-PET-CT during surveillance.

Serum tumour markers are the least invasive and most accessible follow-up investigations. The established serum tumour markers, such as AFP, β -hCG, and LDH, may yield false positive results, so their levels should be correlated with imaging findings or repeated in serial measurements [280]. Serum tumour markers can detect microscopic disease that is not yet visible on cross-sectional imaging in a small proportion of patients, and therefore, they should be measured at the recommended prescribed intervals [281].

MiR-371a-3p has a high diagnostic accuracy for detecting all histologies of GCT except teratoma and has potential to detect disease recurrence earlier than AFP, β -hCG, LDH, or cross-sectional imaging [282]. However, before this promising test can be recommended in routine practice, a validated assay and cut-off definitions in prospective cohorts are required to mitigate the risk of false positive findings, unnecessary restaging, anxiety, or over-treatment.

Regarding the use of US examination of the contralateral testis, the majority of the consensus meeting participants did not support repeat US investigation, either with negative biopsy or if no contralateral biopsy has been performed [271].

A very late relapse (VLR) after five years is a rare event occurring in approximately 0.5% of patients based on a population-based analysis [260]. The aim of follow-up beyond five years therefore shifts to detection of late side effects of treatment and imaging tests are not routinely recommended.

Most patients with VLR are diagnosed due to symptoms, although in up to 50% elevated tumour markers are present in NSGCTs [260, 283]. Patient education regarding relapse symptoms and clinician awareness are important elements of survivorship management. Early use of imaging and tumour markers with suspicion of relapse is encouraged.

Table 10: Recommended minimal follow-up for seminoma clinical stage I on active surveillance or after adjuvant treatment (carboplatin or radiotherapy)

Modality	Year 1	Year 2	Year 3	Years 4 & 5	After 5 years
Tumour markers ± doctor visit	2 times	2 times	2 times	Once	Further management according to survivorship care plan
Chest X-ray	-	-	-	-	
Abdominopelvic magnetic resonance imaging (MRI)/ computed tomography (CT)	2 times	2 times	Once at 36 months	Once at 60 months	

Table 11: Recommended minimal follow-up for non-seminoma clinical stage I on active surveillance

Modality	Year 1	Year 2	Year 3	Year 4 & 5	After 5 years
Tumour markers ± doctor visit	4 times*	4 times	2 times	1-2 times	Further management according to survivorship care plan
Chest X-ray	2 times	2 times	Once, in case of LVI+	At 60 months if LVI+	
Abdominopelvic magnetic resonance imaging (MRI)/ computed tomography (CT)	2 times	At 24 months**	Once at 36 months***	Once at 60 months***	

* In case of high-risk (LVI+) a minority of the consensus group members recommended six times.

** In case of high-risk (LVI+) a majority of the consensus group members recommended an additional CT at eighteen months.

*** Recommended by 50% of the consensus group members.

LVI+ = Lymphovascular invasion present

Table 12: Recommended minimal follow-up after adjuvant treatment or complete remission for advanced disease (excluded: poor-prognosis and no remission)

Modality	Year 1	Year 2	Year 3	Year 4 & 5	After 5 years
Tumour markers ± doctor visit	4 times	4 times	2 times	2 times	Further management according to survivorship care plan**
Chest X-ray	1-2 times	Once	Once	Once	
Abdominopelvic magnetic resonance imaging (MRI)/ computed tomography (CT)	1-2 times	At 24 months	Once at 36 months	Once at 60 months	
Thorax CT	1-2 times*	At 24 months*	Once at 60 months*	Once at 60 months*	

* In conjunction with abdominopelvic MRI/CT in case of pulmonary metastases at diagnosis.

** In case of teratoma in resected residual disease: the patient should remain with the uro-oncologist.

7.2 Quality of life and long-term toxicities after cure of testicular cancer

The vast majority of patients will be cured with five-year relative survival rates of approximately 95% in Western Europe. Testicular cancer patients are usually between 18-40 years of age at diagnosis and life expectancy after cure extends over several decades [284]. Patients should be informed before treatment of common long-term toxicities, which are avoided or minimised by adherence to international guidelines.

During follow-up, patients should be screened and treated for known risk factors such as hypertension, hyperlipidaemia, and testosterone deficiency. Adverse health outcomes (AHOs) are more commonly found in TC patients who received chemotherapy than those cured by surgery alone. Further, modifiable risk factors do contribute to AHOs like hypertension and noise exposure to hearing impairment or smoking to Raynaud phenomenon [285]. Therefore, a healthy lifestyle should be promoted during the follow-up consultations. Adverse health outcomes are associated with unemployment, which is found clearly increased in TC survivors (TCSs) as compared to a male normative population [286]. When follow-up by the TC clinician is terminated, a written cancer survivorship plan addressing late toxic effects, lifestyle recommendations, recurrence risk, and cancer-specific follow-up may be helpful [203, 287].

*For more information regarding long term toxicities and quality of life issues, please see appendix 3, available online <https://uroweb.org/guidelines/testicular-cancer/publications-appendices>

8. RARE ADULT PARA- AND TESTICULAR TUMOURS

Less than 5% of testicular cancers are unrelated to GCNIS and lack 12p alterations [288, 289]. These tumours are rare with available literature based on case reports and small retrospective series. Given the rarity of non-germ cell para-/testicular cancers, referral of these cases to specialist units for multidisciplinary discussion including central image and pathology review is highly recommended. As a result of publication bias related to these types of study, the risk of metastatic disease may be less than that reported in the literature.

8.1 Classification

These testicular tumours have a similar presentation as TC and are only identified after histopathologic examination. They are classified according to the WHO Classification of Tumours of the Urinary System and Male Genital Organs [290].

8.2 Spermatocytic Tumours

Spermatocytic tumours are GCTs unrelated to GCNIS. They may show a unique amplification of chromosome 9 corresponding to the DMRT1 gene and are never associated with other forms of germ cell tumours [290].

Spermatocytic tumours are rare, occur exclusively in the testis and do not normally show elevated tumour markers [290]. Previously named "spermatocytic seminomas" they have been recently reclassified as spermatocytic tumours [290]. As those tumours cannot be differentiated from seminoma GCT by FSE, radical orchiectomy is the standard treatment option. Outcomes after testis-sparing surgery or adjuvant treatment is unknown and therefore not recommended [291]. Metastatic disease is very rare, usually associated with 'sarcomatoid change' and typically presents at or soon after initial diagnosis with limited survival [291].

8.3 Sex cord-stromal tumours

Sex cord–stromal tumours are relatively uncommon but represent the second largest group of primary testicular tumours after GCT's [292]. As a small subset of these tumours are clinically malignant, a thorough evaluation of those morphological features associated with malignancy should be performed to guide management. Two or more of the following features are associated with malignant potential: size > 5 cm, infiltrative borders, cytological atypia, three or more mitotic figures per ten high-power fields, vascular invasion and necrosis [292].

8.3.1 **Leydig cell tumours**

Leydig cell tumours comprise about 4% of adult testicular tumours [293]. These mainly present as localised tumours with metastases occurring in only 2.5% [294]. They may present with hormonal manifestations, including gynecomastia and more rarely are accompanied by Cushing's Syndrome [389]. With testis-sparing surgery a local recurrence rate of 7% has been reported although no adjuvant treatment options can be recommended [295]. Several risk factors for metastatic disease have been proposed which may guide image-guided follow-up intensity [295]. Survival of men with metastatic disease is poor but occasional responses to surgical resection, if feasible, and to a lesser extent systemic treatment have been reported [295].

8.3.2 **Sertoli cell tumours**

Sertoli cell tumours account for approximately 1% of testicular neoplasms [292]. The risk of metastases is unclear. With testis sparing surgery a local recurrence rate of < 1% has been reported although no adjuvant treatment options can be recommended [296]. Several risk factors for metastatic disease have been proposed which may guide image guided follow-up intensity [296]. Survival of men with metastatic disease is poor although response to surgery has been occasionally reported [296].

8.3.3 **Granulosa cell tumour**

Granulosa cell tumours, which include adult and juvenile variants, are extremely rare and metastatic potential is unclear [292]. With testis sparing surgery a local recurrence rate of 5% has been reported although no adjuvant treatment options can be recommended [297]. Whereas metastatic disease has never been reported in juvenile granulosa cell tumours, men with adult type may occasionally present with metastatic disease [297]. Survival of men with metastatic disease is poor although rare instances of response to surgical or systemic treatment has been reported [297].

8.3.4 **Thecoma/fibroma group of tumours**

These tumours derive from the testicular parenchymal stroma or from the tunica albuginea. They seem to be uniformly benign [292, 298].

8.3.5 **Paratesticular tumours of the epididymis or spermatic cord**

The majority of epididymal masses are benign cystic or inflammatory conditions. Solid epididymal tumours are rare and comprise numerous benign and neoplastic lesions. In the only population-based analyses [299], the majority of neoplastic lesions of the epididymis or spermatic cord were sarcomas, metastases from other organs or primary adenocarcinomas similar to proportions reported in institutional studies [300, 301]. Benign lesions, which may comprise the majority in clinical practice include lipomas, adenomatoid tumours leiomyomas and papillary cystadenomas.

Robust criteria to differentiate between neoplastic benign lesions have not been defined although ultrasonography with or without fine needle aspiration [302] MRI [53, 303] or surgical exploration with FSE or histopathological confirmation can be considered. No clear recommendation can be provided regarding surgical approach, extent of resection and neo- or adjuvant treatment can be given.

8.4 **Mesothelioma of the tunica vaginalis testis**

Mesothelioma of the tunica vaginalis testis is a rare but aggressive disease [304]. Beside older age, larger tumour size, presence of necrosis, angiolymphatic invasion or a high mitotic index the only modifiable risk factors represents local recurrence. Therefore, aggressive local treatment with hemiscrotectomy is recommended. No clear recommendation can be given regarding adjuvant treatment. In case of metastatic disease, the median overall survival is a few months only and multimodal treatment could be considered.

8.5 **Follow-up of rare adult para- and testicular cancers**

After local surgical treatment is completed, attention turns to follow-up strategies with the aims of detecting recurrence or secondary cancers at a stage when further curative procedures are possible whilst minimising the burden of follow-up and the potential for over-treatment and concomitant treatment toxicity. Data for rare para- and testicular cancers are limited but recommended follow-up schedules based on published case series have been suggested [305].

9. REFERENCES

1. Patrikidou, A., *et al.* European Association of Urology Guidelines on Testicular Cancer: 2023 Update. *Eur Urol*, 2023. 84: 289.
<https://pubmed.ncbi.nlm.nih.gov/37183161/>
2. Phillips, B. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
<https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009/>
3. Guyatt, G.H., *et al.* Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.
<https://pubmed.ncbi.nlm.nih.gov/18467413/>
4. Park, J.S., *et al.* Recent global trends in testicular cancer incidence and mortality. *Medicine (Baltimore)*, 2018. 97: e12390.
<https://pubmed.ncbi.nlm.nih.gov/30213007/>
5. Nigam, M., *et al.* Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. *World J Urol*, 2015. 33: 623.
<https://pubmed.ncbi.nlm.nih.gov/25030752/>
6. Gurney, J.K., *et al.* International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. *Eur Urol*, 2019. 76: 615.
<https://pubmed.ncbi.nlm.nih.gov/31324498/>
7. Huang, J., *et al.* Worldwide Distribution, Risk Factors, and Temporal Trends of Testicular Cancer Incidence and Mortality: A Global Analysis. *Eur Urol Oncol*, 2022. 5: 566.
<https://pubmed.ncbi.nlm.nih.gov/35863988/>
8. Znaor, A., *et al.* Global patterns in testicular cancer incidence and mortality in 2020. *Int J Cancer*, 2022. 151: 692.
<https://pubmed.ncbi.nlm.nih.gov/35277970/>
9. Oosterhuis, J.W., *et al.* Testicular germ-cell tumours in a broader perspective. *Nat Rev Cancer*, 2005. 5: 210.
<https://pubmed.ncbi.nlm.nih.gov/15738984/>
10. Looijenga, L.H.J., *et al.* Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. *Am J Surg Pathol*, 2020. 44: e66.
<https://pubmed.ncbi.nlm.nih.gov/32205480/>
11. Jorgensen, N., *et al.* Testicular dysgenesis syndrome comprises some but not all cases of hypospadias and impaired spermatogenesis. *Int J Androl*, 2010. 33: 298.
<https://pubmed.ncbi.nlm.nih.gov/20132348/>
12. Lip, S.Z., *et al.* A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. *Arch Dis Child*, 2013. 98: 20.
<https://pubmed.ncbi.nlm.nih.gov/23193201/>
13. Del Giudice, F., *et al.* Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. *Fertil Steril*, 2020. 114: 984.
<https://pubmed.ncbi.nlm.nih.gov/32709378/>
14. Slowikowska-Hilczer, J., *et al.* Risk of gonadal neoplasia in patients with disorders/differences of sex development. *Cancer Epidemiol*, 2020. 69: 101800.
<https://pubmed.ncbi.nlm.nih.gov/32905884/>
15. Mostert, M.M., *et al.* Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p-amplicon. *Cancer Genet Cytogenet*, 1996. 89: 146.
<https://pubmed.ncbi.nlm.nih.gov/8697422/>
16. Bosl, G.J., *et al.* Testicular germ-cell cancer. *N Engl J Med*, 1997. 337: 242.
<https://pubmed.ncbi.nlm.nih.gov/9227931/>
17. Greene, M.H., *et al.* Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. *Endocr Relat Cancer*, 2010. 17: R109.
<https://pubmed.ncbi.nlm.nih.gov/20228134/>
18. Lutke Holzik, M.F., *et al.* Genetic predisposition to testicular germ-cell tumours. *Lancet Oncol*, 2004. 5: 363.
<https://pubmed.ncbi.nlm.nih.gov/15172357/>

19. Kharazmi, E., *et al.* Cancer Risk in Relatives of Testicular Cancer Patients by Histology Type and Age at Diagnosis: A Joint Study from Five Nordic Countries. *Eur Urol*, 2015. 68: 283.
<https://pubmed.ncbi.nlm.nih.gov/25913387/>
20. Schaapveld, M., *et al.* Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. *Br J Cancer*, 2012. 107: 1637.
<https://pubmed.ncbi.nlm.nih.gov/23059747/>
21. Peng, X., *et al.* The association risk of male subfertility and testicular cancer: a systematic review. *PLoS One*, 2009. 4: e5591.
<https://pubmed.ncbi.nlm.nih.gov/19440348/>
22. Seikkula, H., *et al.* Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. *Cancer Epidemiol*, 2020. 69: 101807.
<https://pubmed.ncbi.nlm.nih.gov/33045472/>
23. Maroto, P., *et al.* Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. *Urol Oncol*, 2021. 39: 135 e17.
<https://pubmed.ncbi.nlm.nih.gov/33189529/>
24. Blok, J.M., *et al.* Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. *J Clin Oncol*, 2021. 39: 319.
<https://pubmed.ncbi.nlm.nih.gov/33119475/>
25. Hellesnes, R., *et al.* Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study. *J Clin Oncol*, 2021. 39: 308.
<https://pubmed.ncbi.nlm.nih.gov/33356420/>
26. Pluta, J., *et al.* Identification of 22 susceptibility loci associated with testicular germ cell tumors. *Nat Commun*, 2021. 12: 4487.
<https://pubmed.ncbi.nlm.nih.gov/34301922/>
27. Moch, H., *et al.* The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*, 2022. 82: 458.
<https://pubmed.ncbi.nlm.nih.gov/35853783/>
28. Brierley, J.E., *et al.*, The TNM Classification of Malignant Tumours 8th edition. 2016.
29. Amin, M.B., *et al.*, AJCC Cancer Staging Manual. 8th ed. AJCC Cancer Staging Manual. 2017.
30. Klepp, O., *et al.* Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchietomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). *Ann Oncol*, 1990. 1: 281.
<https://pubmed.ncbi.nlm.nih.gov/1702312/>
31. Verhoeven, R.H., *et al.* Markedly increased incidence and improved survival of testicular cancer in the Netherlands. *Acta Oncol*, 2014. 53: 342.
<https://pubmed.ncbi.nlm.nih.gov/23992111/>
32. Warde, P., *et al.* Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. *J Clin Oncol*, 2002. 20: 4448.
<https://pubmed.ncbi.nlm.nih.gov/12431967/>
33. Chung, P., *et al.* Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. *Cancer Med*, 2015. 4: 155.
<https://pubmed.ncbi.nlm.nih.gov/25236854/>
34. Mortensen, M.S., *et al.* A nationwide cohort study of stage I seminoma patients followed on a surveillance program. *Eur Urol*, 2014. 66: 1172.
<https://pubmed.ncbi.nlm.nih.gov/25064686/>
35. Aparicio, J., *et al.* Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). *Ann Oncol*, 2014. 25: 2173.
<https://pubmed.ncbi.nlm.nih.gov/25210015/>
36. Tandstad, T., *et al.* Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). *Ann Oncol*, 2016. 27: 1299.
<https://pubmed.ncbi.nlm.nih.gov/27052649/>
37. Boormans, J.L., *et al.* Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. *Eur Urol*, 2018. 73: 394.
<https://pubmed.ncbi.nlm.nih.gov/29100813/>

38. Zengerling, F., *et al.* Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. *Urol Oncol*, 2018. 36: 448.
<https://pubmed.ncbi.nlm.nih.gov/28712790/>
39. Verrill, C., *et al.* Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. *Am J Surg Pathol*, 2018. 42: e33.
<https://pubmed.ncbi.nlm.nih.gov/29579010/>
40. Albers, P., *et al.* Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. *J Clin Oncol*, 2003. 21: 1505.
<https://pubmed.ncbi.nlm.nih.gov/12697874/>
41. Blok, J.M., *et al.* Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis. *BJU Int*, 2020. 125: 355.
<https://pubmed.ncbi.nlm.nih.gov/31797520/>
42. Zengerling, F., *et al.* Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review. *World J Urol*, 2022. 40: 2879.
<https://pubmed.ncbi.nlm.nih.gov/35906286/>
43. Lobo, J., *et al.* Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas. *Am J Surg Pathol*, 2019. 43: 1711.
<https://pubmed.ncbi.nlm.nih.gov/31490238/>
44. Verrill, C., *et al.* Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. *Am J Surg Pathol*, 2017. 41: e22.
<https://pubmed.ncbi.nlm.nih.gov/28368923/>
45. Mead, G.M., *et al.* The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. *Clin Oncol (R Coll Radiol)*, 1997. 9: 207.
<https://pubmed.ncbi.nlm.nih.gov/9315391/>
46. Gillessen, S., *et al.* Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. *J Clin Oncol*, 2021. 39: 1563.
<https://pubmed.ncbi.nlm.nih.gov/33822655/>
47. Beyer, J., *et al.* Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. *J Clin Oncol*, 2021. 39: 1553.
<https://pubmed.ncbi.nlm.nih.gov/33729863/>
48. Germa-Lluch, J.R., *et al.* Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). *Eur Urol*, 2002. 42: 553.
<https://pubmed.ncbi.nlm.nih.gov/12477650/>
49. Angulo, J.C., *et al.* Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms). *J Urol*, 2009. 182: 2303.
<https://pubmed.ncbi.nlm.nih.gov/19762049/>
50. Ager, M., *et al.* Radiological features characterising indeterminate testes masses: a systematic review and meta-analysis. *BJU Int*, 2023. 131: 288.
<https://pubmed.ncbi.nlm.nih.gov/35980855/>
51. Chavarriaga, J., *et al.* Small Testicular Masses: Contemporary Diagnostic and Treatment Strategies, Future Directions, and Knowledge Gaps. *Urol Oncol*, 2023. 41: 331.
<https://pubmed.ncbi.nlm.nih.gov/36990940/>
52. Henriques, D., *et al.* Prevalence and Management of Incidental Testicular Masses-A Systematic Review. *J Clin Med*, 2022. 11: 5770.
<https://pubmed.ncbi.nlm.nih.gov/36233639/>
53. Tsili, A.C., *et al.* When to ask for an MRI of the scrotum. *Andrology*, 2021. 9: 1395.
<https://pubmed.ncbi.nlm.nih.gov/33964115/>
54. de Wit, M., *et al.* [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. *Ann Oncol*, 2008. 19: 1619.
<https://pubmed.ncbi.nlm.nih.gov/18453520/>
55. Huddart, R.A., *et al.* 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. *J Clin Oncol*, 2007. 25: 3090.
<https://pubmed.ncbi.nlm.nih.gov/17634488/>

56. Busch, J., *et al.* Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. *World J Urol*, 2022. 40: 2843.
<https://pubmed.ncbi.nlm.nih.gov/35037965/>
57. Pasoglou, V., *et al.* Whole Body MRI in the Detection of Lymph Node Metastases in Patients with Testicular Germ Cell Cancer. *Life (Basel)*, 2022. 12.
<https://pubmed.ncbi.nlm.nih.gov/35207499/>
58. Feldman, D.R., *et al.* Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. *J Clin Oncol*, 2016. 34: 345.
<https://pubmed.ncbi.nlm.nih.gov/26460295/>
59. Sutcliffe, P., *et al.* A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression. *Health Technol Assess*, 2013. 17: 1.
<https://pubmed.ncbi.nlm.nih.gov/24070110/>
60. Kaufmann, T.J., *et al.* Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. *Neuro Oncol*, 2020. 22: 757.
<https://pubmed.ncbi.nlm.nih.gov/32048719/>
61. Dieckmann, K.P., *et al.* Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment. *Biomed Res Int*, 2019. 2019: 5030349.
<https://pubmed.ncbi.nlm.nih.gov/31275973/>
62. Nicholson, B.D., *et al.* The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. *Cancer Epidemiol*, 2019. 59: 15.
<https://pubmed.ncbi.nlm.nih.gov/30658216/>
63. Dieckmann, K.P., *et al.* Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. *World J Urol*, 2022. 40: 317.
<https://pubmed.ncbi.nlm.nih.gov/34775512/>
64. Leao, R., *et al.* Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. *Eur Urol*, 2021. 80: 456.
<https://pubmed.ncbi.nlm.nih.gov/34175151/>
65. Belge, G., *et al.* Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. *J Cancer Res Clin Oncol*, 2021. 147: 435.
<https://pubmed.ncbi.nlm.nih.gov/33200255/>
66. Lafin, J., *et al.* Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range. *Res Sq*, 2023.
<https://pubmed.ncbi.nlm.nih.gov/36993198/>
67. Patel, H.D., *et al.* Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis. *Urol Oncol*, 2020. 38: 344.
<https://pubmed.ncbi.nlm.nih.gov/32192891/>
68. Dieckmann, K.P., *et al.* Carcinoma *in situ* of the testis: review of biological and clinical features. *Int J Cancer*, 1999. 83: 815.
<https://pubmed.ncbi.nlm.nih.gov/10597201/>
69. Nason, G.J., *et al.* Partial orchiectomy: The Princess Margaret cancer centre experience. *Urol Oncol*, 2020. 38: 605 e19.
<https://pubmed.ncbi.nlm.nih.gov/32284257/>
70. Dieckmann, K.P., *et al.* Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. *Eur Urol*, 2007. 51: 175.
<https://pubmed.ncbi.nlm.nih.gov/16814456/>
71. Fankhauser, C.D., *et al.* The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. *Eur Urol Focus*, 2021. 7: 1400.
<https://pubmed.ncbi.nlm.nih.gov/32684510/>
72. Bieniek, J.M., *et al.* Prevalence and Management of Incidental Small Testicular Masses Discovered on Ultrasonographic Evaluation of Male Infertility. *J Urol*, 2018. 199: 481.
<https://pubmed.ncbi.nlm.nih.gov/28789946/>

73. Scandura, G., *et al.* Incidentally detected testicular lesions <10 mm in diameter: can orchidectomy be avoided? *BJU Int*, 2018. 121: 575.
<https://pubmed.ncbi.nlm.nih.gov/29032579/>
74. Favilla, V., *et al.* Oncological and functional outcomes of testis sparing surgery in small testicular mass: a systematic review. *Minerva Urol Nephrol*, 2021. 73: 431.
<https://pubmed.ncbi.nlm.nih.gov/33949185/>
75. Grogg, J.B., *et al.* Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases. *World J Urol*, 2022. 40: 2293.
<https://pubmed.ncbi.nlm.nih.gov/35821265/>
76. Skoogh, J., *et al.* Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. *Int J Androl*, 2011. 34: 183.
<https://pubmed.ncbi.nlm.nih.gov/20550599/>
77. Robinson, R., *et al.* Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. *BJU Int*, 2016. 117: 249.
<https://pubmed.ncbi.nlm.nih.gov/25168859/>
78. Dieckmann, K.P., *et al.* Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. *J Clin Oncol*, 1996. 14: 3126.
<https://pubmed.ncbi.nlm.nih.gov/8955658/>
79. Ruf, C.G., *et al.* Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia. *Andrology*, 2015. 3: 92.
<https://pubmed.ncbi.nlm.nih.gov/25146646/>
80. Andreassen, K.E., *et al.* Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). *Int J Cancer*, 2011. 129: 2867.
<https://pubmed.ncbi.nlm.nih.gov/21626506/>
81. Harland, S.J., *et al.* Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. *J Urol*, 1998. 160: 1353.
<https://pubmed.ncbi.nlm.nih.gov/9751353/>
82. Tabernero, J., *et al.* Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. *J Urol*, 2004. 171: 164.
<https://pubmed.ncbi.nlm.nih.gov/14665868/>
83. Albers, P., *et al.* Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. *Urology*, 1999. 54: 714.
<https://pubmed.ncbi.nlm.nih.gov/10510934/>
84. Heidenreich, A., *et al.* Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? *Semin Urol Oncol*, 2002. 20: 234.
<https://pubmed.ncbi.nlm.nih.gov/12489055/>
85. Giwercman, A., *et al.* Prevalence of carcinoma *in situ* and other histopathological abnormalities in testes of men with a history of cryptorchidism. *J Urol*, 1989. 142: 998.
<https://pubmed.ncbi.nlm.nih.gov/2571738/>
86. Souchon, R., *et al.* Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy. *Strahlenther Onkol*, 2006. 182: 289.
<https://pubmed.ncbi.nlm.nih.gov/16673063/>
87. Moch, H., *et al.*, WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. 2016, Lyon.
88. Berney, D.M., *et al.* Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. *Histopathology*, 2019. 74: 171.
<https://pubmed.ncbi.nlm.nih.gov/30565308/>
89. Kuczyk, M.A., *et al.* Alterations of the p53 tumor suppressor gene in carcinoma *in situ* of the testis. *Cancer*, 1996. 78: 1958.
<https://pubmed.ncbi.nlm.nih.gov/8909317/>
90. Force, U.S.P.S.T. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med*, 2011. 154: 483.
<https://pubmed.ncbi.nlm.nih.gov/21464350/>
91. Ilic, D., *et al.* Screening for testicular cancer. *Cochrane Database Syst Rev*, 2011: CD007853.
<https://pubmed.ncbi.nlm.nih.gov/21328302/>
92. Chong, R.I.H., *et al.* Testicular self-examination for early detection of testicular cancer. *World J Urol*, 2023. 41: 941.
<https://pubmed.ncbi.nlm.nih.gov/37036497/>

93. Høe-Hansen, C.E., *et al.* Carcinoma *in situ* testis, the progenitor of testicular germ cell tumours: a clinical review. *Ann Oncol*, 2005. 16: 863.
<https://pubmed.ncbi.nlm.nih.gov/15821122/>
94. Petersen, P.M., *et al.* Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. *J Clin Oncol*, 2002. 20: 1537.
<https://pubmed.ncbi.nlm.nih.gov/11896102/>
95. Dieckmann, K.P., *et al.* Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. *Ann Oncol*, 2013. 24: 1332.
<https://pubmed.ncbi.nlm.nih.gov/23293116/>
96. Classen, J., *et al.* Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. *Br J Cancer*, 2003. 88: 828.
<https://pubmed.ncbi.nlm.nih.gov/12644817/>
97. Stephenson, A., *et al.* Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. *J Urol*, 2019. 202: 272.
<https://pubmed.ncbi.nlm.nih.gov/31059667/>
98. Christensen, T.B., *et al.* Effect of chemotherapy on carcinoma *in situ* of the testis. *Ann Oncol*, 1998. 9: 657.
<https://pubmed.ncbi.nlm.nih.gov/9681081/>
99. Mortensen, M.S., *et al.* Treatment options for carcinoma *in situ* testis. *Int J Androl*, 2011. 34: e32.
<https://pubmed.ncbi.nlm.nih.gov/21651575/>
100. Bokemeyer, C., *et al.* Extragenital germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. *J Clin Oncol*, 2002. 20: 1864.
<https://pubmed.ncbi.nlm.nih.gov/11919246/>
101. Kollmannsberger, C., *et al.* Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. *J Clin Oncol*, 2015. 33: 51.
<https://pubmed.ncbi.nlm.nih.gov/25135991/>
102. Ruf, C.G., *et al.* Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. *World J Urol*, 2022. 40: 2889.
<https://pubmed.ncbi.nlm.nih.gov/36107211/>
103. Groll, R.J., *et al.* A comprehensive systematic review of testicular germ cell tumor surveillance. *Crit Rev Oncol Hematol*, 2007. 64: 182.
<https://pubmed.ncbi.nlm.nih.gov/17644403/>
104. Nayan, M., *et al.* Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. *Eur Urol*, 2017. 71: 120.
<https://pubmed.ncbi.nlm.nih.gov/27527805/>
105. Tandstad, T., *et al.* Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. *J Clin Oncol*, 2011. 29: 719.
<https://pubmed.ncbi.nlm.nih.gov/21205748/>
106. Chung, P., *et al.* Management of stage I seminomatous testicular cancer: a systematic review. *Clin Oncol (R Coll Radiol)*, 2010. 22: 6.
<https://pubmed.ncbi.nlm.nih.gov/19775876/>
107. Huang, M.M., *et al.* Cost-effectiveness Analysis of Non-risk-adapted Active Surveillance for Postorchietomy Management of Clinical Stage I Seminoma. *Eur Urol Focus*, 2021. 7: 1409.
<https://pubmed.ncbi.nlm.nih.gov/32646809/>
108. Oliver, R.T., *et al.* Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). *J Clin Oncol*, 2011. 29: 957.
<https://pubmed.ncbi.nlm.nih.gov/21282539/>
109. Fischer, S., *et al.* Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. *J Clin Oncol*, 2017. 35: 194.
<https://pubmed.ncbi.nlm.nih.gov/27893332/>
110. Powles, T., *et al.* The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. *Ann Oncol*, 2008. 19: 443.
<https://pubmed.ncbi.nlm.nih.gov/18048383/>

111. Bieri, S., *et al.* Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? *Radiother Oncol*, 1999. 50: 349.
<https://pubmed.ncbi.nlm.nih.gov/10392822/>
112. van den Belt-Dusebout, A.W., *et al.* Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol*, 2007. 25: 4370.
<https://pubmed.ncbi.nlm.nih.gov/17906202/>
113. Horwich, A., *et al.* Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. *Br J Cancer*, 2014. 110: 256.
<https://pubmed.ncbi.nlm.nih.gov/24263066/>
114. Patel, H.D., *et al.* Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. *Urol Oncol*, 2017. 35: 606 e1.
<https://pubmed.ncbi.nlm.nih.gov/28712791/>
115. Aparicio, J., *et al.* Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. *Clin Transl Oncol*, 2021. 23: 58.
<https://pubmed.ncbi.nlm.nih.gov/32462393/>
116. Hamilton, R.J., *et al.* Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. *J Clin Oncol*, 2019. 37: 1919.
<https://pubmed.ncbi.nlm.nih.gov/30802156/>
117. Kollmannsberger, C., *et al.* Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. *Ann Oncol*, 2010. 21: 1296.
<https://pubmed.ncbi.nlm.nih.gov/19875756/>
118. Nichols, C.R., *et al.* Active surveillance is the preferred approach to clinical stage I testicular cancer. *J Clin Oncol*, 2013. 31: 3490.
<https://pubmed.ncbi.nlm.nih.gov/24002502/>
119. Donohue, J.P., *et al.* Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. *J Urol*, 1993. 149: 237.
<https://pubmed.ncbi.nlm.nih.gov/8381190/>
120. Nicolai, N., *et al.* Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. *Eur Urol*, 2010. 58: 912.
<https://pubmed.ncbi.nlm.nih.gov/20817343/>
121. Nicolai, N., *et al.* Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. *J Urol*, 2018. 199: 741.
<https://pubmed.ncbi.nlm.nih.gov/28964782/>
122. Al-Ahmadie, H.A., *et al.* Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. *Urology*, 2013. 82: 1341.
<https://pubmed.ncbi.nlm.nih.gov/24094656/>
123. Douglawi, A., *et al.* Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. *J Urol*, 2020. 204: 96.
<https://pubmed.ncbi.nlm.nih.gov/32003612/>
124. Ghoreifi, A., *et al.* Re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, *et al.* Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? *J Clin Oncol*. In press. <https://doi.org/10.1200/JCO.22.00118>: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? *Eur Urol*, 2023. 83: e18.
<https://pubmed.ncbi.nlm.nih.gov/36195480/>
125. Heidenreich, A., *et al.* Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. *J Urol*, 2003. 169: 1710.
<https://pubmed.ncbi.nlm.nih.gov/12686815/>
126. Albers, P., *et al.* Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *J Clin Oncol*, 2008. 26: 2966.
<https://pubmed.ncbi.nlm.nih.gov/18458040/>

127. Pearce, S.M., *et al.* Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. *Eur Urol*, 2017. 71: 476.
<https://pubmed.ncbi.nlm.nih.gov/27234998/>
128. Calaway, A.C., *et al.* Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. *Eur Urol*, 2019. 76: 607.
<https://pubmed.ncbi.nlm.nih.gov/31174891/>
129. Rodrigues, G.J., *et al.* Robot-assisted retroperitoneal lymphadenectomy: The state of art. *Asian J Urol*, 2021. 8: 27.
<https://pubmed.ncbi.nlm.nih.gov/33569270/>
130. Bhanvadia, R., *et al.* Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. *World J Urol*, 2021. 39: 1977.
<https://pubmed.ncbi.nlm.nih.gov/32797261/>
131. Schermerhorn, S.M.V., *et al.* Learning Curve for Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection. *J Endourol*, 2021. 35: 1483.
<https://pubmed.ncbi.nlm.nih.gov/33559522/>
132. Supron, A.D., *et al.* Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. *J Robot Surg*, 2021. 15: 309.
<https://pubmed.ncbi.nlm.nih.gov/32572754/>
133. Taylor, J., *et al.* Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort. *Eur Urol Focus*, 2021. 7: 1403.
<https://pubmed.ncbi.nlm.nih.gov/32682794/>
134. Hiester, A., *et al.* Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. *J Urol*, 2020. 204: 1242.
<https://pubmed.ncbi.nlm.nih.gov/32717162/>
135. Foster, R.S., *et al.* Clinical stage I nonseminoma: surgery versus surveillance. *Semin Oncol*, 1998. 25: 145.
<https://pubmed.ncbi.nlm.nih.gov/9562447/>
136. Cullen, M.H., *et al.* Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. *J Clin Oncol*, 1996. 14: 1106.
<https://pubmed.ncbi.nlm.nih.gov/8648364/>
137. Pont, J., *et al.* Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. *J Clin Oncol*, 1996. 14: 441.
<https://pubmed.ncbi.nlm.nih.gov/8636755/>
138. Chevreau, C., *et al.* Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. *Eur Urol*, 2004. 46: 209.
<https://pubmed.ncbi.nlm.nih.gov/15245815/>
139. Bohlen, D., *et al.* Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. *J Urol*, 2001. 165: 441.
<https://pubmed.ncbi.nlm.nih.gov/11176393/>
140. Tandstad, T., *et al.* Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. *J Clin Oncol*, 2009. 27: 2122.
<https://pubmed.ncbi.nlm.nih.gov/19307506/>
141. Tandstad, T., *et al.* One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. *Ann Oncol*, 2014. 25: 2167.
<https://pubmed.ncbi.nlm.nih.gov/25114021/>
142. Flechtner, H.H., *et al.* Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. *Eur Urol*, 2016. 69: 518.
<https://pubmed.ncbi.nlm.nih.gov/26620368/>
143. Huddart, R.A., *et al.* Cardiovascular disease as a long-term complication of treatment for testicular cancer. *J Clin Oncol*, 2003. 21: 1513.
<https://pubmed.ncbi.nlm.nih.gov/12697875/>
144. Westermann, D.H., *et al.* Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. *J Urol*, 2008. 179: 163.
<https://pubmed.ncbi.nlm.nih.gov/18001800/>

145. Fischer, S., *et al.* Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. *J Clin Oncol*, 2020. 38: 1322.
<https://pubmed.ncbi.nlm.nih.gov/31877087/>
146. Giannatempo, P., *et al.* Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. *J Urol*, 2016. 196: 95.
<https://pubmed.ncbi.nlm.nih.gov/26748165/>
147. Hajiran, A., *et al.* Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. *Ann Surg Oncol*, 2021. 28: 3648.
<https://pubmed.ncbi.nlm.nih.gov/33689081/>
148. Harari, S.E., *et al.* Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. *Urol Oncol*, 2017. 35: 605 e9.
<https://pubmed.ncbi.nlm.nih.gov/28647396/>
149. International Prognostic Factors Study, G., *et al.* Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. *J Clin Oncol*, 2010. 28: 4906.
<https://pubmed.ncbi.nlm.nih.gov/20956623/>
150. Aparicio, J., *et al.* Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. *J Urol*, 2019. 202: 742.
<https://pubmed.ncbi.nlm.nih.gov/31163007/>
151. Olofsson, S.E., *et al.* Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. *J Clin Oncol*, 2011. 29: 2032.
<https://pubmed.ncbi.nlm.nih.gov/21482994/>
152. Classen, J., *et al.* Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. *J Clin Oncol*, 2003. 21: 1101.
<https://pubmed.ncbi.nlm.nih.gov/12637477/>
153. Chung, P.W., *et al.* Stage II testicular seminoma: patterns of recurrence and outcome of treatment. *Eur Urol*, 2004. 45: 754.
<https://pubmed.ncbi.nlm.nih.gov/15149748/>
154. Giannatempo, P., *et al.* Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. *Ann Oncol*, 2015. 26: 657.
<https://pubmed.ncbi.nlm.nih.gov/25214543/>
155. Heinzlbecker, J., *et al.* Therapy of clinical stage IIA and IIB seminoma: a systematic review. *World J Urol*, 2022. 40: 2829.
<https://pubmed.ncbi.nlm.nih.gov/34779882/>
156. Culine, S., *et al.* Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). *Ann Oncol*, 2007. 18: 917.
<https://pubmed.ncbi.nlm.nih.gov/17351252/>
157. Hellesnes, R., *et al.* Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. *Int J Cancer*, 2020. 147: 21.
<https://pubmed.ncbi.nlm.nih.gov/31597192/>
158. Daneshmand, S., *et al.* Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. *J Clin Oncol*, 2023. 41: 3009.
<https://pubmed.ncbi.nlm.nih.gov/36913642/>
159. Hiester, A., *et al.* Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). *Eur Urol*, 2023. 84: 25.
<https://pubmed.ncbi.nlm.nih.gov/36372627/>
160. Heidenreich, A., *et al.* Testis-sparing Surgery in Adult Patients with Germ Cell Tumors: Systematic Search of the Literature and Focused Review. *Eur Urol Focus*, 2023. 9: 244.
<https://pubmed.ncbi.nlm.nih.gov/36418210/>
161. Tachibana, I., *et al.* Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward? *J Clin Oncol*, 2023. 41: 3930.
<https://pubmed.ncbi.nlm.nih.gov/36730902/>
162. Matulewicz, R.S., *et al.* Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum. *J Urol*, 2023: 101097JU0000000000003697.
<https://pubmed.ncbi.nlm.nih.gov/37672753/>

163. Loriot, Y., *et al.* The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. *Eur Urol*, 2022. 82: 172.
<https://pubmed.ncbi.nlm.nih.gov/35599187/>
164. Papachristofilou, A., *et al.* Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*, 2022. 23: 1441.
<https://pubmed.ncbi.nlm.nih.gov/36228644/>
165. Neuschwander, A., *et al.* Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. *Eur Urol Focus*, 2023. 9: 541.
<https://pubmed.ncbi.nlm.nih.gov/36379869/>
166. Nicolai, N., *et al.* Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy. *Tumori*, 2023. 109: 379.
<https://pubmed.ncbi.nlm.nih.gov/35915559/>
167. McHugh, D.J., *et al.* Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. *J Clin Oncol*, 2020. 38: 1332.
<https://pubmed.ncbi.nlm.nih.gov/32109195/>
168. Stephenson, A.J., *et al.* Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. *J Clin Oncol*, 2007. 25: 5597.
<https://pubmed.ncbi.nlm.nih.gov/18065732/>
169. Bokemeyer, C., *et al.* Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. *Br J Cancer*, 2004. 91: 683.
<https://pubmed.ncbi.nlm.nih.gov/15266338/>
170. de Wit, R., *et al.* Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. *J Clin Oncol*, 1997. 15: 1837.
<https://pubmed.ncbi.nlm.nih.gov/9164193/>
171. de Wit, R., *et al.* Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. *J Clin Oncol*, 2001. 19: 1629.
<https://pubmed.ncbi.nlm.nih.gov/11250991/>
172. Fossa, S.D., *et al.* Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). *J Clin Oncol*, 2003. 21: 1107.
<https://pubmed.ncbi.nlm.nih.gov/12637478/>
173. Grimson, P.S., *et al.* Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. *J Natl Cancer Inst*, 2010. 102: 1253.
<https://pubmed.ncbi.nlm.nih.gov/20631341/>
174. de Wit, R., *et al.* Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. *European Organization for Research and Treatment of Cancer. Br J Cancer*, 1998. 78: 828.
<https://pubmed.ncbi.nlm.nih.gov/9743309/>
175. Nichols, C.R., *et al.* Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. *J Clin Oncol*, 1998. 16: 1287.
<https://pubmed.ncbi.nlm.nih.gov/9552027/>
176. Daugaard, G., *et al.* A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSSG, and Grupo Germinal (EORTC 30974). *Ann Oncol*, 2011. 22: 1054.
<https://pubmed.ncbi.nlm.nih.gov/21059637/>

177. Motzer, R.J., *et al.* Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. *J Clin Oncol*, 2007. 25: 247.
<https://pubmed.ncbi.nlm.nih.gov/17235042/>
178. Fizazi, K., *et al.* Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. *J Clin Oncol*, 2004. 22: 3868.
<https://pubmed.ncbi.nlm.nih.gov/15302906/>
179. Fizazi, K., *et al.* Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. *Lancet Oncol*, 2014. 15: 1442.
<https://pubmed.ncbi.nlm.nih.gov/25456363/>
180. Kollmannsberger, C., *et al.* Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. *Ann Oncol*, 2000. 11: 1115.
<https://pubmed.ncbi.nlm.nih.gov/11061604/>
181. Winter, C., *et al.* How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. *World J Urol*, 2022. 40: 2863.
<https://pubmed.ncbi.nlm.nih.gov/35554637/>
182. Bokemeyer, C., *et al.* First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. *Br J Cancer*, 2003. 89: 29.
<https://pubmed.ncbi.nlm.nih.gov/12838296/>
183. Collette, L., *et al.* Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. *J Natl Cancer Inst*, 1999. 91: 839.
<https://pubmed.ncbi.nlm.nih.gov/10340903/>
184. Massard, C., *et al.* Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? *Ann Oncol*, 2010. 21: 1585.
<https://pubmed.ncbi.nlm.nih.gov/20181575/>
185. Woldu, S.L., *et al.* Impact of hospital case volume on testicular cancer outcomes and practice patterns. *Urol Oncol*, 2018. 36: 14 e7.
<https://pubmed.ncbi.nlm.nih.gov/28935185/>
186. Gillessen, S., *et al.* Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. *Ann Oncol*, 2010. 21: 1589.
<https://pubmed.ncbi.nlm.nih.gov/20164149/>
187. Khorana, A.A., *et al.* Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. *N Engl J Med*, 2019. 380: 720.
<https://pubmed.ncbi.nlm.nih.gov/30786186/>
188. Carrier, M., *et al.* Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. *N Engl J Med*, 2019. 380: 711.
<https://pubmed.ncbi.nlm.nih.gov/30511879/>
189. Agnelli, G., *et al.* Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. *N Engl J Med*, 2012. 366: 601.
<https://pubmed.ncbi.nlm.nih.gov/22335737/>
190. Agnelli, G., *et al.* Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol*, 2009. 10: 943.
<https://pubmed.ncbi.nlm.nih.gov/19726226/>
191. Key, N.S., *et al.* Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*, 2020. 38: 496.
<https://pubmed.ncbi.nlm.nih.gov/31381464/>
192. Gizzi, M., *et al.* Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. *Eur J Cancer*, 2016. 69: 151.
<https://pubmed.ncbi.nlm.nih.gov/27821318/>
193. Fankhauser, C.D., *et al.* A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. *Eur Urol Focus*, 2021. 7: 1130.
<https://pubmed.ncbi.nlm.nih.gov/33032968/>

194. Haugnes, H.S., *et al.* Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. *Eur Urol Open Sci*, 2021. 32: 19.
<https://pubmed.ncbi.nlm.nih.gov/34667955/>
195. Andre, F., *et al.* The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. *Eur J Cancer*, 2000. 36: 1389.
<https://pubmed.ncbi.nlm.nih.gov/10899652/>
196. Che, Y., *et al.* Late relapsing germ cell tumors with elevated tumor markers. *World J Urol*, 2022. 40: 363.
<https://pubmed.ncbi.nlm.nih.gov/34518930/>
197. Fossa, S.D., *et al.* Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. *Br J Cancer*, 1999. 80: 1392.
<https://pubmed.ncbi.nlm.nih.gov/10424741/>
198. Hofmockel, G., *et al.* Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. *Urol Int*, 1996. 57: 38.
<https://pubmed.ncbi.nlm.nih.gov/8840489/>
199. Kamat, M.R., *et al.* Value of retroperitoneal lymph node dissection in advanced testicular seminoma. *J Surg Oncol*, 1992. 51: 65.
<https://pubmed.ncbi.nlm.nih.gov/1381455/>
200. Motzer, R., *et al.* Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. *J Clin Oncol*, 1987. 5: 1064.
<https://pubmed.ncbi.nlm.nih.gov/3598610/>
201. De Santis, M., *et al.* 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. *J Clin Oncol*, 2004. 22: 1034.
<https://pubmed.ncbi.nlm.nih.gov/15020605/>
202. Bachner, M., *et al.* 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. *Ann Oncol*, 2012. 23: 59.
<https://pubmed.ncbi.nlm.nih.gov/21460378/>
203. Beyer, J., *et al.* Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol*, 2013. 24: 878.
<https://pubmed.ncbi.nlm.nih.gov/23152360/>
204. Oechsle, K., *et al.* [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. *J Clin Oncol*, 2008. 26: 5930.
<https://pubmed.ncbi.nlm.nih.gov/19018083/>
205. Cathomas, R., *et al.* Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. *J Clin Oncol*, 2018. 36: JCO1800210.
<https://pubmed.ncbi.nlm.nih.gov/30285559/>
206. Herr, H.W., *et al.* Surgery for a post-chemotherapy residual mass in seminoma. *J Urol*, 1997. 157: 860.
<https://pubmed.ncbi.nlm.nih.gov/9072586/>
207. Mosharafa, A.A., *et al.* Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? *J Urol*, 2003. 169: 2126.
<https://pubmed.ncbi.nlm.nih.gov/12771733/>
208. Puc, H.S., *et al.* Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. *J Clin Oncol*, 1996. 14: 454.
<https://pubmed.ncbi.nlm.nih.gov/8636757/>
209. Conduit, C., *et al.* A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours. *Front Oncol*, 2022. 12: 931509.
<https://pubmed.ncbi.nlm.nih.gov/36059636/>
210. Nason, G.J., *et al.* Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. *Eur Urol Oncol*, 2021. 4: 289.
<https://pubmed.ncbi.nlm.nih.gov/32907779/>

211. Ehrlich, Y., *et al.* Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? *J Clin Oncol*, 2010. 28: 531.
<https://pubmed.ncbi.nlm.nih.gov/20026808/>
212. Hartmann, J.T., *et al.* Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. *Eur J Cancer*, 1997. 33: 843.
<https://pubmed.ncbi.nlm.nih.gov/9291803/>
213. Hendry, W.F., *et al.* Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. *Cancer*, 2002. 94: 1668.
<https://pubmed.ncbi.nlm.nih.gov/11920527/>
214. Sheinfeld, J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. *Semin Urol Oncol*, 2002. 20: 262.
<https://pubmed.ncbi.nlm.nih.gov/12489059/>
215. Steyerberg, E.W., *et al.* Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. *Int J Cancer*, 1999. 83: 856.
<https://pubmed.ncbi.nlm.nih.gov/10597211/>
216. Carver, B.S., *et al.* Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. *J Clin Oncol*, 2007. 25: 1033.
<https://pubmed.ncbi.nlm.nih.gov/17261854/>
217. Oldenburg, J., *et al.* Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. *J Clin Oncol*, 2003. 21: 3310.
<https://pubmed.ncbi.nlm.nih.gov/12947067/>
218. Antonelli, L., *et al.* Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. *Eur J Cancer*, 2023. 182: 144.
<https://pubmed.ncbi.nlm.nih.gov/36787661/>
219. Rick, O., *et al.* Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. *J Clin Oncol*, 2004. 22: 3713.
<https://pubmed.ncbi.nlm.nih.gov/15365067/>
220. Heidenreich, A., *et al.* Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. *Eur Urol*, 2009. 55: 217.
<https://pubmed.ncbi.nlm.nih.gov/18926622/>
221. Gerdtsen, A., *et al.* Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. *Eur Urol Oncol*, 2022. 5: 235.
<https://pubmed.ncbi.nlm.nih.gov/33750683/>
222. Beck, S.D., *et al.* Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? *Cancer*, 2007. 110: 1235.
<https://pubmed.ncbi.nlm.nih.gov/17665498/>
223. Large, M.C., *et al.* Retroperitoneal lymph node dissection: reassessment of modified templates. *BJU Int*, 2009. 104: 1369.
<https://pubmed.ncbi.nlm.nih.gov/19840015/>
224. Fizazi, K., *et al.* Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. *Ann Oncol*, 2008. 19: 259.
<https://pubmed.ncbi.nlm.nih.gov/18042838/>
225. Busch, J., *et al.* Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer—a single center analysis. *BMC Urol*, 2012. 12: 15.
<https://pubmed.ncbi.nlm.nih.gov/22651395/>
226. Arai, Y., *et al.* Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. *Int Urol Nephrol*, 2012. 44: 1389.
<https://pubmed.ncbi.nlm.nih.gov/22648291/>
227. Nicolai, N., *et al.* Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. *J Endourol*, 2016. 30: 1112.
<https://pubmed.ncbi.nlm.nih.gov/27533924/>

228. Fankhauser, C.D., *et al.* Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. *World J Urol*, 2022. 40: 1505.
<https://pubmed.ncbi.nlm.nih.gov/35279732/>
229. Steyerberg, E.W., *et al.* Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. *J Urol*, 1997. 158: 474.
<https://pubmed.ncbi.nlm.nih.gov/9224327/>
230. Besse, B., *et al.* Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. *J Thorac Cardiovasc Surg*, 2009. 137: 448.
<https://pubmed.ncbi.nlm.nih.gov/19185168/>
231. Schirren, J., *et al.* The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. *Thorac Cardiovasc Surg*, 2012. 60: 405.
<https://pubmed.ncbi.nlm.nih.gov/22383152/>
232. Ehrlich, Y., *et al.* Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. *Urology*, 2009. 73: 442 e17.
<https://pubmed.ncbi.nlm.nih.gov/18436290/>
233. Heidenreich, A., *et al.* Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. *Ann Oncol*, 2017. 28: 362.
<https://pubmed.ncbi.nlm.nih.gov/27831507/>
234. Winter, C., *et al.* Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. *Eur Urol*, 2012. 61: 403.
<https://pubmed.ncbi.nlm.nih.gov/22078334/>
235. Wells, H., *et al.* Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study. *BJU Int*, 2017. 119: 91.
<https://pubmed.ncbi.nlm.nih.gov/27353395/>
236. Capitano, U., *et al.* Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. *Urology*, 2009. 74: 373.
<https://pubmed.ncbi.nlm.nih.gov/19501893/>
237. Flechon, A., *et al.* Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. *BJU Int*, 2010. 106: 779.
<https://pubmed.ncbi.nlm.nih.gov/20089110/>
238. Eggener, S.E., *et al.* Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. *Cancer*, 2007. 109: 528.
<https://pubmed.ncbi.nlm.nih.gov/17177200/>
239. Oechsle, K., *et al.* Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. *Eur Urol*, 2011. 60: 850.
<https://pubmed.ncbi.nlm.nih.gov/21704446/>
240. Nicolai, N., *et al.* Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. *BJU Int*, 2009. 104: 340.
<https://pubmed.ncbi.nlm.nih.gov/19239440/>
241. Beck, S.D., *et al.* Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. *J Clin Oncol*, 2005. 23: 6149.
<https://pubmed.ncbi.nlm.nih.gov/16135481/>
242. Fizazi, K., *et al.* Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. *J Clin Oncol*, 2001. 19: 2647.
<https://pubmed.ncbi.nlm.nih.gov/11352956/>
243. Antonelli, L., *et al.* Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. *J Clin Oncol*, 2023: JCO2300443.
<https://pubmed.ncbi.nlm.nih.gov/37656935/>
244. Miller, K.D., *et al.* Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. *J Clin Oncol*, 1997. 15: 1427.
<https://pubmed.ncbi.nlm.nih.gov/9193335/>

245. Fizazi, K., *et al.* Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. *Ann Oncol*, 2014. 25: 987.
<https://pubmed.ncbi.nlm.nih.gov/24595454/>
246. Mead, G.M., *et al.* A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. *Br J Cancer*, 2005. 93: 178.
<https://pubmed.ncbi.nlm.nih.gov/15999102/>
247. Lorch, A., *et al.* Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. *J Clin Oncol*, 2012. 30: 800.
<https://pubmed.ncbi.nlm.nih.gov/22291076/>
248. Oechsle, K., *et al.* Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. *Oncology*, 2010. 78: 47.
<https://pubmed.ncbi.nlm.nih.gov/20215785/>
249. Agarwala, A.K., *et al.* Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. *Am J Clin Oncol*, 2011. 34: 286.
<https://pubmed.ncbi.nlm.nih.gov/20523207/>
250. Berger, L.A., *et al.* First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). *J Cancer Res Clin Oncol*, 2014. 140: 1211.
<https://pubmed.ncbi.nlm.nih.gov/24696231/>
251. Massard, C., *et al.* Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. *Ann Oncol*, 2013. 24: 322.
<https://pubmed.ncbi.nlm.nih.gov/23104726/>
252. Necchi, A., *et al.* Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. *Bone Marrow Transplant*, 2016. 51: 384.
<https://pubmed.ncbi.nlm.nih.gov/26642334/>
253. Bin Riaz, I., *et al.* Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. *Bone Marrow Transplant*, 2018. 53: 1242.
<https://pubmed.ncbi.nlm.nih.gov/29703969/>
254. Taza, F., *et al.* Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT). *Clin Genitourin Cancer*, 2023. 21: 213.
<https://pubmed.ncbi.nlm.nih.gov/36737276/>
255. Necchi, A., *et al.* Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. *Clin Genitourin Cancer*, 2014. 12: 63.
<https://pubmed.ncbi.nlm.nih.gov/24161525/>
256. Mulherin, B.P., *et al.* Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. *Am J Clin Oncol*, 2015. 38: 373.
<https://pubmed.ncbi.nlm.nih.gov/26214082/>
257. Lorch, A., *et al.* Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. *J Clin Oncol*, 2007. 25: 2778.
<https://pubmed.ncbi.nlm.nih.gov/17602082/>
258. Jay, A.P.M., *et al.* Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour. *Eur Urol Open Sci*, 2021. 29: 82.
<https://pubmed.ncbi.nlm.nih.gov/34337537/>
259. Oldenburg, J., *et al.* Late relapses of germ cell malignancies: incidence, management, and prognosis. *J Clin Oncol*, 2006. 24: 5503.
<https://pubmed.ncbi.nlm.nih.gov/17158535/>
260. Oldenburg, J., *et al.* Late recurrences of germ cell malignancies: a population-based experience over three decades. *Br J Cancer*, 2006. 94: 820.
<https://pubmed.ncbi.nlm.nih.gov/16508636/>
261. Richardson, N.H., *et al.* Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only. *Clin Genitourin Cancer*, 2023. 21: 467.
<https://pubmed.ncbi.nlm.nih.gov/37088659/>

262. Baniel, J., *et al.* Late relapse of testicular cancer. *J Clin Oncol*, 1995. 13: 1170.
<https://pubmed.ncbi.nlm.nih.gov/7537800/>
263. George, D.W., *et al.* Update on late relapse of germ cell tumor: a clinical and molecular analysis. *J Clin Oncol*, 2003. 21: 113.
<https://pubmed.ncbi.nlm.nih.gov/12506179/>
264. Alifrangis, C., *et al.* Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery. *Eur Urol Focus*, 2021. 7: 835.
<https://pubmed.ncbi.nlm.nih.gov/32381397/>
265. Moore, J.A., *et al.* Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. *Cancers (Basel)*, 2022. 14: 1127.
<https://pubmed.ncbi.nlm.nih.gov/35267435/>
266. Lee, A.H., *et al.* The value of central histopathological review of testicular tumours before treatment. *BJU Int*, 1999. 84: 75.
<https://pubmed.ncbi.nlm.nih.gov/10444128/>
267. Lipphardt, M.E., *et al.* Late relapse of testicular cancer. *World J Urol*, 2004. 22: 47.
<https://pubmed.ncbi.nlm.nih.gov/15064970/>
268. Fossa, S.D., *et al.* Treatment outcome of patients with brain metastases from malignant germ cell tumors. *Cancer*, 1999. 85: 988.
<https://pubmed.ncbi.nlm.nih.gov/10091779/>
269. Bokemeyer, C., *et al.* Treatment of brain metastases in patients with testicular cancer. *J Clin Oncol*, 1997. 15: 1449.
<https://pubmed.ncbi.nlm.nih.gov/9193339/>
270. Hartmann JT, *et al.* Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. *Proc Ann Soc Clin Oncol*, 2003. 22.
<https://www.sciencedirect.com/science/article/pii/S1359634903908755/>
271. Honecker, F., *et al.* ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. *Ann Oncol*, 2018. 29: 1658.
<https://pubmed.ncbi.nlm.nih.gov/30113631/>
272. Hale, G.R., *et al.* Lymph node imaging in testicular cancer. *Transl Androl Urol*, 2018. 7: 864.
<https://pubmed.ncbi.nlm.nih.gov/30456189/>
273. Joffe, J.K., *et al.* Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). *J Clin Oncol*, 2022. 40: 2468.
<https://pubmed.ncbi.nlm.nih.gov/35298280/>
274. Thomas, K.L., *et al.* The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance. *Transl Androl Urol*, 2020. 9: S3.
<https://pubmed.ncbi.nlm.nih.gov/32055480/>
275. Sohaib, S.A., *et al.* Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. *Clin Radiol*, 2009. 64: 362.
<https://pubmed.ncbi.nlm.nih.gov/19264179/>
276. Laukka, M., *et al.* Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. *Acta Oncol*, 2020. 59: 660.
<https://pubmed.ncbi.nlm.nih.gov/32048533/>
277. Loughrey, G.J., *et al.* The value of specialist oncological radiology review of cross-sectional imaging. *Clin Radiol*, 1999. 54: 149.
<https://pubmed.ncbi.nlm.nih.gov/10201861/>
278. Larsen, S.K.A., *et al.* Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. *Acta Oncol*, 2020. 59: 1374.
<https://pubmed.ncbi.nlm.nih.gov/32684054/>
279. Conduit, C., *et al.* Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. *Cancer Imaging*, 2022. 22: 58.
<https://pubmed.ncbi.nlm.nih.gov/36209121/>
280. Fischer, S., *et al.* The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. *Eur Urol Open Sci*, 2023. 50: 57.
<https://pubmed.ncbi.nlm.nih.gov/36874175/>
281. Kaufmann, E., *et al.* Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review. *Eur Urol Open Sci*, 2022. 44: 142.
<https://pubmed.ncbi.nlm.nih.gov/36106144/>

282. Fankhauser, C.D., *et al.* Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. *Br J Cancer*, 2022. 126: 1140.
<https://pubmed.ncbi.nlm.nih.gov/34912073/>
283. Mortensen, M.S., *et al.* Late Relapses in Stage I Testicular Cancer Patients on Surveillance. *Eur Urol*, 2016. 70: 365.
<https://pubmed.ncbi.nlm.nih.gov/26996661/>
284. Travis, L.B., *et al.* Testicular cancer survivorship: research strategies and recommendations. *J Natl Cancer Inst*, 2010. 102: 1114.
<https://pubmed.ncbi.nlm.nih.gov/20585105/>
285. Agrawal, V., *et al.* Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. *JNCI Cancer Spectr*, 2020. 4: pkz079.
<https://pubmed.ncbi.nlm.nih.gov/32190815/>
286. Kerns, S.L., *et al.* Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. *JNCI Cancer Spectr*, 2020. 4: pkaa022.
<https://pubmed.ncbi.nlm.nih.gov/32704617/>
287. Haugnes, H.S., *et al.* Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. *J Clin Oncol*, 2012. 30: 3752.
<https://pubmed.ncbi.nlm.nih.gov/23008318/>
288. Alberti, K.G., *et al.* The metabolic syndrome—a new worldwide definition. *Lancet*, 2005. 366: 1059.
<https://pubmed.ncbi.nlm.nih.gov/16182882/>
289. Giannoulatou, E., *et al.* Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. *PLoS One*, 2017. 12: e0178169.
<https://pubmed.ncbi.nlm.nih.gov/28542371/>
290. Moch, H., *et al.* The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*, 2016. 70: 93.
<https://pubmed.ncbi.nlm.nih.gov/26935559/>
291. Grogg, J.B., *et al.* A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis. *J Cancer Res Clin Oncol*, 2019. 145: 3037.
<https://pubmed.ncbi.nlm.nih.gov/31646373/>
292. Idrees, M.T., *et al.* The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. *Histopathology*, 2017. 70: 513.
<https://pubmed.ncbi.nlm.nih.gov/27801954/>
293. Corcioni, B., *et al.* Multiparametric ultrasound for the diagnosis of Leydig cell tumours in non-palpable testicular lesions. *Andrology*, 2022. 10: 1387.
<https://pubmed.ncbi.nlm.nih.gov/35842907/>
294. Ruf, C.G., *et al.* Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. *World J Urol*, 2020. 38: 2857.
<https://pubmed.ncbi.nlm.nih.gov/31960106/>
295. Fankhauser, C.D., *et al.* Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. *J Urol*, 2020. 203: 949.
<https://pubmed.ncbi.nlm.nih.gov/31845841/>
296. Grogg, J., *et al.* Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. *Oncologist*, 2020. 25: 585.
<https://pubmed.ncbi.nlm.nih.gov/32043680/>
297. Grogg, J.B., *et al.* Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. *J Cancer Res Clin Oncol*, 2020. 146: 2829.
<https://pubmed.ncbi.nlm.nih.gov/32719989/>
298. Zhang, M., *et al.* Testicular fibrothecoma: a morphologic and immunohistochemical study of 16 cases. *Am J Surg Pathol*, 2013. 37: 1208.
<https://pubmed.ncbi.nlm.nih.gov/23715159/>
299. Bhambhani, H.P., *et al.* Primary malignancies of the epididymis: clinical characteristics and prognostic factors. *Can J Urol*, 2021. 28: 10522.
<https://pubmed.ncbi.nlm.nih.gov/33625342/>
300. Chowdhry, V.K., *et al.* Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure. *Sarcoma*, 2021. 2021: 8824301.
<https://pubmed.ncbi.nlm.nih.gov/33746565/>
301. Radaelli, S., *et al.* Prognostic factors and outcome of spermatic cord sarcoma. *Ann Surg Oncol*, 2014. 21: 3557.
<https://pubmed.ncbi.nlm.nih.gov/24802908/>

302. Bharti, J.N., *et al.* Cytomorphological spectrum of epididymal nodules: An institution's experience. *Cytojournal*, 2017. 14: 26.
<https://pubmed.ncbi.nlm.nih.gov/29259652/>
303. Tsili, A.C., *et al.* MRI of the scrotum: Recommendations of the ESUR Scrotal and Penile Imaging Working Group. *Eur Radiol*, 2018. 28: 31.
<https://pubmed.ncbi.nlm.nih.gov/28698942/>
304. Grogg, J.B., *et al.* Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. *J Cancer Res Clin Oncol*, 2021. 147: 2671.
<https://pubmed.ncbi.nlm.nih.gov/33559739/>
305. Fankhauser, C.D., *et al.* Treatment and follow-up of rare testis tumours. *J Cancer Res Clin Oncol*, 2022. 148: 667.
<https://pubmed.ncbi.nlm.nih.gov/35048196/>

10. CONFLICT OF INTEREST

All members of the Testicular Cancer Guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publicly accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines>.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.

If a publisher and/or location is required, include:

EAU Guidelines Office, Arnhem, the Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>

References to individual guidelines should be structured in the following way:

Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.